

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



AN

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/86, 5/10, A61K 48/00		A1	(11) International Publication Number: WO 00/15820 (43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/US99/20718 (22) International Filing Date: 10 September 1999 (10.09.99) (30) Priority Data: 60/099,791 10 September 1998 (10.09.98) US Not furnished 9 September 1999 (09.09.99) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARJPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): CALYDON, INC. [US/US]; 1324 Chesapeake Terrace, Sunnyvale, CA 94089 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): YU, De, Chao [CN/US]; 1046 Eagle Lane, Foster City, CA 94404 (US). HENDERSON, Daniel, R. [US/US]; 955 Matadero Avenue, Palo Alto, CA 94306 (US). (74) Agents: POLIZZI, Catherine, M. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).			
(54) Title: ADENOVIRUS VECTORS CONTAINING CELL STATUS-SPECIFIC RESPONSE ELEMENTS AND METHODS OF USE THEREOF			
<p style="text-align: center;">CN796 The diagram illustrates the structure of an adenoviral vector. It features a horizontal line representing the genome. On the left, the label "CN796" is written above the line. Above the line, two specific regulatory elements are labeled: "HRE" and "PSE". Below the line, two genes are labeled: "E1A" and "E1B". The "E1A" gene is positioned to the left of the "E1B" gene. The "HRE" and "PSE" elements are located between the two genes. There are small square boxes at the ends of the line, likely indicating restriction sites or vector ends.</p>			
(57) Abstract <p>The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A "cell status" is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ADENOVIRUS VECTORS CONTAINING CELL STATUS-SPECIFIC RESPONSE ELEMENTS AND METHODS OF USE THEREOF

5

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the priority benefit of U.S. Provisional Patent Application No.60/099,791, filed September 10, 1998. The priority application is hereby incorporated herein by reference in its entirety.

10

**STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER
FEDERALLY SPONSORED RESEARCH**

(Not Applicable)

TECHNICAL FIELD

15

This invention relates to cell transfection using adenoviral vectors. More specifically, it relates to cell status-specific replication of adenovirus vectors in cells, regardless of tissue or cell type.

BACKGROUND ART

20

In spite of numerous advances in medical research, cancer remains the second leading cause of death in the United States. In the industrialized nations, roughly one in five persons will die of cancer. Traditional modes of clinical care, such as surgical resection, radiotherapy and chemotherapy, have a significant failure rate, especially for solid tumors. Neoplasia resulting in benign tumors can usually be completely cured by removing the mass surgically. If a tumor becomes malignant, as manifested by invasion of surrounding tissue, it becomes much more difficult to eradicate. Once a malignant tumor metastasizes, it is much less likely to be eradicated.

Excluding basal cell carcinoma, there are over one million new cases of cancer per year in the United States alone, and cancer accounts for over one half million deaths per year in this

country. In the world as a whole, the five most common cancers are those of lung, stomach, breast, colon/rectum, and uterine cervix, and the total number of new cases per year is over 6 million.

Lung cancer is one of the most refractory of solid tumors because inoperable cases are up to 60% and the 5-year survival is only 13%. In particular, adenocarcinomas, which comprise about one-half of the total lung cancer cases, are mostly chemo-radioresistant. Colorectal cancer is the third most common cancer and the second leading cause of cancer deaths. Pancreatic cancer is virtually always fatal. Thus, current treatment prospects for many patients with these carcinomas are unsatisfactory, and the prognosis is poor.

Hepatocellular carcinoma (HCC or malignant hepatoma) is one of the most common cancers in the world, and is especially problematic in Asia. Treatment prospects for patients with hepatocellular carcinoma are dim. Even with improvements in therapy and availability of liver transplant, only a minority of patients are cured by removal of the tumor either by resection or transplantation. For the majority of patients, the current treatments remain unsatisfactory, and the prognosis is poor.

Breast cancer is one of the most common cancers in the United States, with an annual incidence of about 182,000 new cases and nearly 50,000 deaths. In the industrial nations, approximately one in eight women can expect to develop breast cancer. The mortality rate for breast cancer has remained unchanged since 1930. It has increased an average of 0.2% per year, but decreased in women under 65 years of age by an average of 0.3% per year. See e.g., Marchant (1994) *Contemporary Management of Breast Disease II: Breast Cancer*, in: *Obstetrics and Gynecology Clinics of North America* 21:555-560; and Colditz (1993) *Cancer Suppl.* 71:1480-1489.

Despite ongoing improvement in the understanding of the disease, breast cancer has remained resistant to medical intervention. Most clinical initiatives are focused on early diagnosis, followed by conventional forms of intervention, particularly surgery and chemotherapy. Such interventions are of limited success, particularly in patients where the tumor has undergone metastasis. There is a pressing need to improve the arsenal of therapies available to provide more precise and more effective treatment in a less invasive way.

Prostate cancer is the fastest growing neoplasm in men with an estimated 244,000 new cases in the United States being diagnosed in 1995, of which approximately 44,000 deaths will result. Prostate cancer is now the most frequently diagnosed cancer in men. Prostate cancer is latent; many men carry prostate cancer cells without overt signs of disease. It is associated 5 with a high morbidity. Cancer metastasis to bone (late stage) is common and is almost always fatal.

Current treatments include radical prostatectomy, radiation therapy, hormonal ablation and chemotherapy. Unfortunately, in approximately 80% of cases, diagnosis of prostate cancer is established when the disease has already metastasized to the bones, thus limiting the 10 effectiveness of surgical treatments. Hormonal therapy frequently fails with time with the development of hormone-resistant tumor cells. Although chemotherapeutic agents have been used in the treatment of prostate cancer, no single agent has demonstrated superiority over its counterparts, and no drug combination seems particularly effective. The generally drug-resistant, slow-growing nature of most prostate cancers makes them particularly unresponsive 15 to standard chemotherapy.

A major, indeed the overwhelming, obstacle to cancer therapy is the problem of selectivity; that is, the ability to inhibit the multiplication of tumor cells, while leaving unaffected the function of normal cells. For example, in prostate cancer therapy, the therapeutic ratio, or ratio of tumor cell killing to normal cell killing of traditional tumor 20 chemotherapy, is only 1.5:1. Thus, more effective treatment methods and pharmaceutical compositions for therapy and prophylaxis of neoplasia are needed.

Solid tumors frequently contain regions that are poorly vascularized, partly because the tumor cells grow faster than the endothelial cells that make up the blood vessels. Tumor cells can remain viable in such hypoxic conditions and are often refractory to chemotherapy and 25 radiation therapy. In a recent study of cervical cancer, the oxygen status of a tumor was shown to be the single most important prognostic factor, ahead of age of patient, menopausal status, clinical stage, size and histology. Hoeckel et al. (1996) *Semin. Radiat. Oncol.* 6:1-8.

Of particular interest is development of more specific, targeted forms of cancer therapy, especially for cancers that are difficult to treat successfully. In contrast to conventional cancer 30 therapies, which result in relatively non-specific and often serious toxicity, more specific

treatment modalities attempt to inhibit or kill malignant cells selectively while leaving healthy cells intact. Radioresistant and chemoresistant tumors present particular challenges, and there is a need for methods of treating these types of tumors.

One possible treatment approach for many of these cancers is gene therapy, whereby a gene of interest is introduced into the malignant cell. Various viral vectors, including adenoviral vectors, have been developed as vehicles for gene therapy. The virtually exclusive focus in development of adenoviral vectors for gene therapy is use of adenovirus merely as a vehicle for introducing the gene of interest, not as an effector in itself. Replication of adenovirus has been viewed as an undesirable result, largely due to the host immune response. In the treatment of cancer by replication-defective adenoviruses, the host immune response limits the duration of repeat doses at two levels. First, the capsid proteins of the adenovirus delivery vehicle itself are immunogenic. Second, viral late genes are frequently expressed in transduced cells, eliciting cellular immunity. Thus, the ability to repeatedly administer cytokines, tumor suppressor genes, ribozymes, suicide genes, or genes which convert prodrug to an active drug has been limited by the immunogenicity of both the gene transfer vehicle and the viral gene products of the transfer vehicle as well as the transient nature of gene expression.

Use of adenoviral vectors as therapeutic vehicles for cancer has been reported. Some of these approaches utilize tissue (i.e., cell type) specific transcriptional regulatory elements to selectively drive adenoviral replication (and thus cytotoxicity). U.S. Pat. No. 5,698,443; see also WO 95/11984; WO 96/17053; WO 96/34969; WO 98/35028. While useful and promising, there remain other treatment contexts for which tissue specific replication may be insufficient.

Besides cancerous cells, it is often desirable to selectively destroy certain unwanted cells or tissues. Besides surgery, however, which is invasive, there is a dearth of methods available, particularly non-invasive methods, which would allow such selective cytotoxicity and/or suppression.

There is a need for vector constructs that are capable of eliminating essentially all cancerous cells in a minimum number of administrations before specific immunological response against the vector prevents further treatment and which are suitable for use in

specific, focused cancer ablation treatments. There is also a need for an ability to selectively destroy, or impair, unwanted cells, regardless of cell type and/or regardless of anatomical location.

5

SUMMARY OF THE INVENTION

Replication-competent adenoviral vectors specific for cells in a given, or particular, physiological state that permits or induces expression of polynucleotides under transcriptional control of a cell status-specific TRE, and methods for their use are provided. In these replication-competent adenovirus vectors, one or more adenoviral genes is under transcriptional control of an cell status-specific transcriptional regulatory element (TRE). Preferably, the adenoviral gene under transcriptional control of a cell status-specific TRE is one that is essential for adenoviral propagation. A transgene under control of the cell status-specific TRE may also be present. For the adenoviral vectors of the present invention, a cell status-specific TRE is active in a cell existing in a particular, reversible, physiological state, which may be an aberrant physiological state, i.e., a physiological state that deviates from the typical, or normal, physiological state of that same cell when in a non-dividing or regulated dividing state under normal, physiological conditions.

Accordingly, in one aspect, the invention provides an adenovirus vector comprising an adenovirus gene, wherein said adenovirus gene is under transcriptional control of a cell status-specific TRE. In another embodiment, a cell status-specific TRE is human. In another embodiment, a cell status-specific TRE comprises a cell status-specific promoter and enhancer. In yet another embodiment, a cell status-specific TRE is juxtaposed with a cell type-specific TRE, and together the two elements control expression of an adenovirus gene. Thus, the invention provides adenovirus vectors comprising a TRE comprising a cell status-specific TRE and a cell type-specific TRE.

In some embodiments, the adenovirus gene under transcriptional control of a cell status-specific TRE is an adenovirus gene essential for replication. In some embodiments, the

adenoviral gene essential for replication is an early gene. In another embodiment, the early gene is E1A. In another embodiment, the early gene is E1B. In yet another embodiment, both E1A and E1B are under transcriptional control of a cell status-specific TRE. In other embodiments, the adenovirus gene essential for replication is a late gene.

5 In another embodiment, the cell status-specific TRE comprises a hypoxia responsive element. In another embodiment, the cell status-specific TRE comprises the nucleotide sequence of SEQ ID NO:1.

10 In another embodiment, the cell status-specific TRE comprises a cell cycle-specific TRE. The cell cycle-specific TRE can be derived from the E2F1 5' flanking region. In one embodiment, the cell cycle-specific TRE comprises the nucleotide sequence depicted in SEQ ID NO:2.

In other embodiments, the adenovirus vector can further comprise a transgene, wherein said transgene is under transcriptional control of an cell status-specific TRE. In some embodiments, the transgene is a cytotoxic gene.

15 In other embodiments, the adenoviral vector comprises an adenoviral gene essential for adenoviral replication under control of a first cell status-specific TRE, and a second adenoviral gene essential for adenoviral replication under control of a second cell status-specific TRE. The first and the second cell status-specific TREs can be identical, substantially identical, or different from, one another.

20 In other embodiments, the adenoviral vector comprises an adenoviral gene essential for adenoviral replication under control of a first cell status-specific TRE, and a transgene under control of a second cell status-specific TRE. The first and the second cell status-specific TREs can be substantially identical to, or different from, one another.

25 In other embodiments, the adenovirus vector comprises an adenovirus gene under transcriptional control of a cell status-specific TRE, and a second adenovirus gene under transcriptional control of a cell type-specific TRE. In other embodiments, the adenovirus vector comprises an adenovirus gene under transcriptional control of a cell status-specific TRE, and a transgene under transcriptional control of a cell type-specific TRE.

30 In another aspect, the invention provides a host cell comprising the adenovirus vector(s) described herein.

In another aspect, the invention provides pharmaceutical compositions comprising an adenovirus vector(s) described herein.

In another aspect, the invention provides kits which contain an adenoviral vector(s) described herein.

5 In another aspect, methods are provided for conferring selective cytotoxicity in target cells (i.e., cells which permit or induce a cell status-specific TRE to function), comprising contacting the cells with an adenovirus vector(s) described herein, whereby the vector enters the cell.

10 Another embodiment of the invention is an adenovirus which replicates preferentially in mammalian cells whose cell status permits or induces the function of a cell status-specific TRE.

15 In another aspect, methods are provided for propagating an adenovirus specific for mammalian cells whose cell status permits the function of a cell status-specific TRE, said method comprising combining an adenovirus vector(s) described herein with mammalian cells whose cell status permits the function of a cell status-specific TRE, whereby said adenovirus is propagated.

20 The invention further provides methods of suppressing tumor cell growth, more particularly a target tumor cell (i.e., a tumor cell that permits or induces a cell status-specific TRE to function), comprising contacting a tumor cell with an adenoviral vector of the invention such that the adenoviral vector enters the tumor cell and exhibits selective cytotoxicity for the tumor cell.

25 In another aspect, methods are provided for detecting cells whose cell status permits the function of a cell status-specific TRE in a biological sample, comprising contacting cells of a biological sample with an adenovirus vector(s) described herein, and detecting replication of the adenovirus vector, if any.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic representation of adenovirus vector CN796, in which the E1A gene is under transcriptional control of an HRE and a PSA-TRE, as described in Example 1.

Figure 2 shows the nucleotide sequence of an HRE from the 5' flanking region of a rat enolase-1 gene (SEQ ID NO:1).

Figure 3 shows the nucleotide sequence of the 5' flanking region of a human E2F1 gene (SEQ ID NO:2). The asterisk indicates the transcription start site.

5 Figure 4 depicts a nucleotide sequence of a prostate-specific antigen TRE.

Figure 5 depicts a nucleotide sequence of a carcinoembryonic antigen TRE.

Figure 6 depicts a nucleotide sequence of a human glandular kallikrein TRE.

Figure 7 depicts a nucleotide sequence of a mucin TRE.

Figure 8 depicts a nucleotide sequence of a rat probasin TRE.

10 Figure 9 depicts a nucleotide sequence and translated amino acid sequence of an adenovirus death protein.

MODES FOR CARRYING OUT THE INVENTION

We have discovered and constructed replication-competent adenovirus vectors which contain an adenoviral gene under transcriptional control of a cell status-specific transcriptional response element (TRE) such that the adenovirus gene is transcribed preferentially in cells whose cell status permit the function of the cell status-specific TRE, and have developed methods using these adenovirus vectors. In some preferred embodiments, the adenovirus vectors of this invention comprise at least one adenovirus gene necessary for adenoviral replication, preferably at least one early gene, under the transcriptional control of a TRE specifically regulated by binding of transcriptional factor(s) and/or co-factor(s) necessary for transcription regulated by the cell status-specific TRE. By providing for cell status-specific transcription of at least one adenovirus gene required for replication, the invention provides adenovirus vectors that can be used for specific cytotoxic effects due to selective replication and/or selective transcription. This is especially useful in the cancer context, in which targeted cell killing is desirable. This is also useful for targeted cytotoxic effects in other, non-tumor cells, when selective destruction and/or suppression of these cells is desirable. The vectors can also be useful for detecting the presence of cells whose cell status permits function of a cell status-specific TRE in, for example, an appropriate biological (such as clinical) sample.

Further, the adenovirus vector(s) can optionally selectively produce one or more proteins of interest in a target cell by using a cell status-specific TRE.

We have found that adenovirus vectors of the invention replicate and/or express an adenoviral gene operably linked to a cell status-specific TRE preferentially in cells whose status permits the function of a cell status-specific TRE. In contrast to previously- described adenoviral vectors designed to replicate preferentially in specific, differentiated cell types, the adenovirus vectors of the present invention comprise regulatory elements that are not cell type-specific. Rather, they confer cell status-specific adenoviral replication and/or cell status-specific expression of an operably linked adenoviral gene and/or transgene.

The adenovirus vectors of the present invention comprise a cell status-specific TRE which is functional in a cell which exhibits a particular physiological (i.e., environmental or metabolic) characteristic which is reversible and/or progressive. The target cell may exhibit an aberrant physiological state, such as low oxygen tension, or may be subjected to an aberrant environmental condition, such as heat or ionizing radiation, in order for the cell-status TRE to function. The replication preference of these vectors is indicated by comparing the level of replication (i.e., titer) in cells in a requisite physiological state or condition (for example, an aberrant physiological state) to the level of replication in cells not exhibiting the requisite physiological state (for example, under normal physiological conditions). Thus, the invention also uses and takes advantage of what has been considered an undesirable aspect of adenoviral vectors, namely, their replication and possibly concomitant immunogenicity. The probability of runaway infection is significantly reduced due to the cell status-specific requirements for viral replication. Without wishing to be bound by any particular theory, the inventors note that production of adenovirus proteins can serve to activate and/or stimulate the immune system, generally and/or specifically toward target cells producing adenoviral proteins, which can be an important consideration in the cancer context, where patients are often moderately to severely immunocompromised.

The adenovirus vectors of the present invention find particular utility in specific treatment regimens, in which the treatment is highly focused toward, for example, a particular cancer which might otherwise be inoperable or untreatable. An important feature of the

invention is that the vectors are useful in these treatments regardless of the tissue or cell type of the cancer, and yet their cytotoxicity can be targeted to certain locations.

General Techniques

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, "Molecular Cloning: A Laboratory Manual", second edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (M.J. Gait, ed., 1984); "Animal Cell Culture" (R.I. Freshney, ed., 1987); "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology" (D.M. Weis & C.C. Blackwell, eds.); "Gene Transfer Vectors for Mammalian Cells" (J.M. Miller & M.P. Calos, eds., 1987); "Current Protocols in Molecular Biology" (F.M. Ausubel et al., eds., 1987); "PCR: The Polymerase Chain Reaction", (Mullis et al., eds., 1994); "Current Protocols in Immunology" (J.E. Coligan et al., eds., 1991).

For techniques related to adenovirus, see, *inter alia*, Felgner and Ringold (1989) *Nature* 337:387-388; Berkner and Sharp (1983) *Nucl. Acids Res.* 11:6003-6020; Graham (1984) *EMBO J.* 3:2917-2922; Bett et al. (1993) *J. Virology* 67:5911-5921; Bett et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:8802-8806.

Definitions

As used herein, a "transcription response element" or "transcriptional regulatory element", or "TRE" is a polynucleotide sequence, preferably a DNA sequence, which increases transcription of an operably linked polynucleotide sequence in a host cell that allows that TRE to function. A TRE can comprise an enhancer and/or a promoter.

As used herein, the term "cell status-specific TRE" is one that confers transcriptional activation on an operably linked polynucleotide in a cell which allows a cell status-specific TRE to function, i.e., a cell which exhibits a particular physiological condition, including, but not limited to, an aberrant physiological state. "Cell status" thus refers to a given, or particular, physiological state (or condition) of a cell, which is reversible and/or progressive. The physiological state may be generated internally or externally; for example, it may be a

metabolic state (such as low oxygen), or it may be generated due to heat or ionizing radiation. "Cell status" is distinct from a "cell type", which relates to a differentiation state of a cell, which under normal conditions is irreversible. Generally (but not necessarily), as discussed herein, a cell status is embodied in an aberrant physiological state, examples of which are given below.

5 A "normal cell status" or "normal physiological state" is the status of a cell which exists in normal physiological conditions and which is non-dividing or divides in a regulated manner, i.e., a cell in a normal physiological state.

10 The terms "aberrant cell status" and "aberrant physiological state", used interchangeably herein, intend a condition of a cell which is a response to, a result of, or is influenced by, an aberrant physiological condition. An aberrant cell status is neither cell type-specific nor tissue type-specific. An aberrant cell status is defined in relation to a cell of the same type which is in a non-dividing/regulated dividing state and under normal physiological conditions.

15 "Normal physiological conditions" are known to those skilled in the art. These conditions may vary, depending on a cell's location in the body. For example, oxygen tension can vary from tissue to tissue. For *in vitro* analyses for the purposes of determining whether a TRE is responsive to deviations from normal physiological conditions, these conditions generally include an oxygen concentration of about 20% O₂, and a temperature of about 37°C. 20 "Regulated cell division" is a term well understood in the art and refers to the normal mitotic activity of a cell. Those skilled in the art understand that normal mitotic activity varies from cell type to cell type. For example, many terminally differentiated cells in tissues exhibit little or no mitotic activity, while hematopoietic cells are generally mitotically active.

25 An "aberrant physiological condition" or "aberrant physiological state", as used herein, intends a condition which deviates from normal physiological conditions, and includes, but is not limited to, a physiological condition that is characterized by alterations in oxygen concentration, such as hypoxic conditions; temperatures which deviate from physiological temperatures; a condition that triggers apoptosis; radiation, including ionizing radiation and UV irradiation; de-regulated cell division, resulting for example, from a lack of, or insufficient amounts of, or inactivity of, a factor which controls cell division, such as, for example,

retinoblastoma protein (Rb); variations in timing of cell cycle; infection with a pathogen; exposure to a chemical substance; or a combination of the above-listed conditions. Another example is a mutation that could, or does, exist in any cell type, i.e., its existence does not depend on, or is not related to, the differentiation state of the cell.

5 A "target cell", as used herein, is one that permits or induces the function of a cell status-specific TRE such that it effects transcriptional activation of an operably linked polynucleotide. A target cell is one which exhibits a requisite physiological (or environmental) state, which may be an aberrant physiological state. Preferably, a target cell is a mammalian cell, preferably a human cell. A target cell may or may not be neoplastic. By transcriptional activation, it is intended that transcription is increased in the target cell above the levels in a control cell (e.g., a that cell when not exhibiting a requisite physiological state (generally a normal physiological state) by at least about 2 fold, preferably at least about 5 fold, preferably at least about 10 fold, more preferably at least about 20 fold, more preferably at least about 50 fold, more preferably at least about 100 fold, more preferably at least about 200 fold, even more preferably at least about 400 fold to about 500 fold, even more preferably at least about 1000 fold. The normal levels are generally the level of activity (if any) in a cell as tested under conditions that activate the cell status-specific TRE, or the level of activity (if any) of a reporter construct lacking a cell status-specific TRE as measured in a cell exhibiting the requisite physiological condition.

10 20 A "functionally-preserved" variant of a cell status-specific TRE is a cell status-specific TRE which differs from another cell status-specific TRE, but still retains cell status cell-specific transcription activity. The difference in an cell status-specific TRE can be due to differences in linear sequence, arising from, for example, single base mutation(s), addition(s), deletion(s), and/or modification(s) of the bases. The difference can also arise from changes in 15 the sugar(s), and/or linkage(s) between the bases of a cell status-specific TRE.

25 An "adenovirus vector" or "adenoviral vector" (used interchangeably) comprises a polynucleotide construct of the invention. A polynucleotide construct of this invention may be in any of several forms, including, but not limited to, DNA, DNA encapsulated in an adenovirus coat, DNA packaged in another viral or viral-like form (such as herpes simplex, and AAV), DNA encapsulated in liposomes, DNA complexed with polylysine, complexed

with synthetic polycationic molecules, conjugated with transferrin, and complexed with compounds such as PEG to immunologically "mask" the molecule and/or increase half-life, and conjugated to a nonviral protein. Preferably, the polynucleotide is DNA. As used herein, "DNA" includes not only bases A, T, C, and G, but also includes any of their analogs or modified forms of these bases, such as methylated nucleotides, internucleotide modifications such as uncharged linkages and thioates, use of sugar analogs, and modified and/or alternative backbone structures, such as polyamides. For purposes of this invention, adenovirus vectors are replication-competent in a target cell.

The terms "polynucleotide" and "nucleic acid", used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. These terms include a single-, double- or triple-stranded DNA, genomic DNA, cDNA, RNA, DNA-RNA hybrid, or a polymer comprising purine and pyrimidine bases, or other natural, chemically, biochemically modified, non-natural or derivatized nucleotide bases. The backbone of the polynucleotide can comprise sugars and phosphate groups (as may typically be found in RNA or DNA), or modified or substituted sugar or phosphate groups. Alternatively, the backbone of the polynucleotide can comprise a polymer of synthetic subunits such as phosphoramidates and thus can be a oligodeoxynucleoside phosphoramidate (P-NH₂) or a mixed phosphoramidate- phosphodiester oligomer. Peyrottes et al. (1996) *Nucleic Acids Res.* 24: 1841-8; Chaturvedi et al. (1996) *Nucleic Acids Res.* 24: 2318-23; Schultz et al. (1996) *Nucleic Acids Res.* 24: 2966-73. A phosphorothiate linkage can be used in place of a phosphodiester linkage. Braun et al. (1988) *J. Immunol.* 141: 2084-9; Latimer et al. (1995) *Mol. Immunol.* 32: 1057-1064. In addition, a double-stranded polynucleotide can be obtained from the single stranded polynucleotide product of chemical synthesis either by synthesizing the complementary strand and annealing the strands under appropriate conditions, or by synthesizing the complementary strand de novo using a DNA polymerase with an appropriate primer.

The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified

nucleotides, such as methylated nucleotides and nucleotide analogs, uracyl, other sugars and linking groups such as fluororibose and thioate, and nucleotide branches. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.

5 Other types of modifications included in this definition are caps, substitution of one or more of the naturally occurring nucleotides with an analog, and introduction of means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides, or a solid support. Preferably, the polynucleotide is DNA. As used herein, "DNA" includes not only bases A, T, C, and G, but also includes any of their analogs or modified forms of these bases, 10 such as methylated nucleotides, internucleotide modifications such as uncharged linkages and thioates, use of sugar analogs, and modified and/or alternative backbone structures, such as polyamides.

A polynucleotide or polynucleotide region has a certain percentage (for example, 80%, 15 85%, 90%, or 95%) of "sequence identity" to another sequence means that, when aligned, that percentage of bases are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in *Current Protocols in Molecular Biology* (F.M. Ausubel et al., eds., 1987) Supplement 30, section 7.7.18, Table 7.7.1. A preferred alignment program 20 is ALIGN Plus (Scientific and Educational Software, Pennsylvania), preferably using default parameters.

"Under transcriptional control" is a term well-understood in the art and indicates that transcription of a polynucleotide sequence, usually a DNA sequence, depends on its being operably (operatively) linked to an element which contributes to the initiation of, or promotes, transcription. "Operably linked" refers to a juxtaposition wherein the elements are in an arrangement allowing them to function.

25 "Replication" and "propagation" are used interchangeably and refer to the ability of a polynucleotide construct of the invention to reproduce, or proliferate. This term is well understood in the art. For purposes of this invention, replication involves production of adenovirus proteins and is generally directed to reproduction of adenovirus. Replication can

be measured using assays standard in the art and described herein, such as a burst assay, plaque assay, or a one-step growth curve assay.

As used herein, "cytotoxicity" is a term well understood in the art and refers to a state in which a cell's usual biochemical or biological activities are compromised (i.e., inhibited).

5 These activities include, but are not limited to, metabolism; cellular replication; DNA replication; transcription; translation; uptake of molecules. "Cytotoxicity" includes cell death and/or cytolysis. Assays are known in the art which indicate cytotoxicity, such as dye exclusion, ³H-thymidine uptake, and plaque assays.

10 The term "selective cytotoxicity", as used herein, refers to the cytotoxicity conferred by an adenovirus vector of the present invention on a cell which allows or induces a cell status-specific TRE to function (a target cell) when compared to the cytotoxicity conferred by an adenoviral vector of the present invention on a cell which does not allow a cell status-specific TRE to function (a non-target cell). Such cytotoxicity may be measured, for example, by plaque assays, by reduction or stabilization in size of a tumor comprising target cells, or the reduction or stabilization of serum levels of a marker characteristic of the tumor cells, or a 15 tissue-specific marker, e.g., a cancer marker, such as prostate specific antigen.

20 In the context of adenovirus, a "heterologous polynucleotide" or "heterologous gene" or "transgene" is any polynucleotide or gene that is not present in wild-type adenovirus. Preferably, the transgene will also not be expressed or present in the target cell prior to introduction by the adenovirus vector. Examples of preferred transgenes are provided below.

In the context of adenovirus, a "heterologous" promoter or enhancer is one which is not associated with or derived from an adenovirus gene.

25 In the context of adenovirus, an "endogenous" promoter, enhancer, or TRE is native to or derived from adenovirus.

In the context of a cell status-specific TRE, a "heterologous" promoter or enhancer is one which is not normally associated in a cell with or derived from a cell status-specific TRE. Examples of a heterologous promoter or enhancer are the albumin promoter or enhancer and other viral promoters and enhancers, such as SV40, or cell type-specific TREs such as a prostate-specific TRE.

A “cell type-specific TRE” is preferentially functional in a specific type of cell relative to other types of cells. In contrast to cell status, “cell type” is a reflection of a differentiation state of a cell which is irreversible. For example, a prostate-specific antigen is expressed in prostate cells, but is not substantially expressed in other cell types such as hepatocytes, 5 astrocytes, cardiocytes, lymphocytes, etc. Generally, a cell type-specific TRE is active in only one cell type. When a cell type-specific TRE is active in more than one cell type, its activity is restricted to a limited number of cell types, i.e., it is not active in all cell types. A cell type-specific TRE may or may not be tumor cell specific.

“Suppressing” tumor growth indicates a growth state that is curtailed when compared 10 to growth without contact with, i.e., transfection by, an adenoviral vector described herein. Tumor cell growth can be assessed by any means known in the art, including, but not limited to, measuring tumor size, determining whether tumor cells are proliferating using a ³H-thymidine incorporation assay, or counting tumor cells. “Suppressing” tumor cell growth means any or all of the following states: slowing, delaying, and stopping tumor growth, as 15 well as tumor shrinkage.

As used herein, the terms “neoplastic cells”, “neoplasia”, “tumor”, “tumor cells”, 20 “cancer” and “cancer cells”, (used interchangeably) refer to cells which exhibit relatively autonomous growth, so that they exhibit an aberrant growth phenotype characterized by a significant loss of control of cell proliferation (i.e., de-regulated cell division). Neoplastic cells can be malignant or benign.

A “host cell” includes an individual cell or cell culture which can be or has been a recipient of an adenoviral vector(s) of this invention. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in total DNA complement) to the original parent cell due to natural, accidental, or deliberate 25 mutation and/or change. A host cell includes cells transfected or infected *in vivo* or *in vitro* with an adenoviral vector of this invention.

“Replication” and “propagation” are used interchangeably and refer to the ability of an adenovirus vector of the invention to reproduce or proliferate. These terms are well understood in the art. For purposes of this invention, replication involves production of 30 adenovirus proteins and is generally directed to reproduction of adenovirus. Replication can

be measured using assays standard in the art and described herein, such as a burst assay or plaque assay. "Replication" and "propagation" include any activity directly or indirectly involved in the process of virus manufacture, including, but not limited to, viral gene expression; production of viral proteins, nucleic acids or other components; packaging of viral components into complete viruses; and cell lysis.

An "ADP coding sequence" is a polynucleotide that encodes ADP or a functional fragment thereof. In the context of ADP, a "functional fragment" of ADP is one that exhibits cytotoxic activity, especially cell lysis, with respect to adenoviral replication. Ways to measure cytotoxic activity are known in the art and are described herein.

A polynucleotide that "encodes" an ADP polypeptide is one that can be transcribed and/or translated to produce an ADP polypeptide or a fragment thereof. The anti-sense strand of such a polynucleotide is also said to encode the sequence.

An "ADP polypeptide" is a polypeptide containing at least a portion, or region, of the amino acid sequence of an ADP (see, for example, SEQ ID NO:5), and which displays a function associated with ADP, particularly cytotoxicity, more particularly, cell lysis. As discussed herein, these functions can be measured using techniques known in the art. It is understood that certain sequence variations may be used, due to, for example, conservative amino acid substitutions, which may provide ADP polypeptides.

A polynucleotide sequence that is "depicted in" a SEQ ID NO means that the sequence is present as an identical contiguous sequence in the SEQ ID NO. The term encompasses portions, or regions of the SEQ ID NO as well as the entire sequence contained within the SEQ ID NO.

A "biological sample" encompasses a variety of sample types obtained from an individual and can be used in a diagnostic or monitoring assay. The definition encompasses blood and other liquid samples of biological origin, solid tissue samples such as a biopsy specimen or tissue cultures or cells derived therefrom, and the progeny thereof. The definition also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as proteins or polynucleotides. The term "biological sample" encompasses a clinical sample, and

also includes cells in culture, cell supernatants, cell lysates, serum, plasma, biological fluid, and tissue samples.

An "individual" is a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, farm animals, sport animals, rodents, primates, and pets.

An "effective amount" is an amount sufficient to effect beneficial or desired results, which may include clinical results. An effective amount can be administered in one or more administrations. For purposes of this invention, an effective amount of an adenoviral vector is an amount that is sufficient to palliate, ameliorate, stabilize, reverse, slow or delay the progression of the disease state.

Adenoviral vectors comprising a cell status-specific TRE

The present invention provides adenoviral vector constructs which comprise an adenovirus gene under transcriptional control of a cell status-specific TRE. Preferably, the adenovirus gene contributes to cytotoxicity (whether direct and/or indirect), more preferably one that contributes to or causes cell death, even more preferably is essential for adenoviral replication. Examples of a gene that contributes to cytotoxicity include, but are not limited to, adenovirus death protein (ADP; discussed below). When the adenovirus vector(s) is selectively (i.e., preferentially) replication competent for propagation in target cells, i.e., cells which permit or induce a cell-status TRE to function, these cells will be preferentially killed upon adenoviral proliferation. Once the target cells are destroyed due to selective cytotoxic and/or cytolytic replication, the adenovirus vector replication is significantly reduced, thus lessening the probability of runaway infection and undesirable bystander effects. *In vitro* cultures may be retained to monitor the mixture (such as, for example, a biopsy or other appropriate biological sample) for occurrence (i.e., presence) and/or recurrence of the target cell, e.g., a neoplastic cell or other undesired cell. To further ensure cytotoxicity, one or more transgenes having a cytotoxic effect may also be present and under selective transcriptional control. In this embodiment, one may provide higher confidence that the target cells will be destroyed. Additionally, or alternatively, an adenovirus gene that contributes to cytotoxicity

and/or cell death (such as ADP) may be included in the adenoviral vector, either free of, or under, selective transcriptional control.

Cell status-specific TREs for use in the adenoviral vectors of the present invention can be derived from any species, preferably a mammal. A number of genes have been described which are expressed in response to, or in association with, a cell status. Any of these cell status-associated genes may be used to generate a cell status-specific TRE.

An example of a cell status is cell cycle. An exemplary gene whose expression is associated with cell cycle is E2F-1, a ubiquitously expressed, growth-regulated gene, which exhibits peak transcriptional activity in S phase. Johnson et al. (1994) *Genes Dev.* 8:1514-1525. The RB protein, as well as other members of the RB family, form specific complexes with E2F-1, thereby inhibiting its ability to activate transcription. Thus, E2F-1-responsive promoters are down-regulated by RB. Many tumor cells have disrupted RB function, which can lead to de-repression of E2F-1-responsive promoters, and, in turn, de-regulated cell division.

Accordingly, in one embodiment, the invention provides an adenoviral vector in which an adenoviral gene (preferably a gene necessary for replication) is under transcriptional control of a cell status-specific TRE, wherein the cell status-specific TRE comprises a cell cycle-activated, or cell-cycle specific, TRE. In one embodiment, the cell cycle-activated TRE is an E2F1 TRE. In one embodiment, this TRE comprises the sequence depicted in Figure 3 and SEQ ID NO:2.

Another group of genes which are regulated by cell status are those whose expression is increased in response to hypoxic conditions. Bunn and Poyton (1996) *Physiol. Rev.* 76:839-885; Dachs and Stratford (1996) *Br. J. Cancer* 74:5126-5132; Guillemin and Krasnow (1997) *Cell* 89:9-12. Many tumors have insufficient blood supply, due in part to the fact that tumor cells typically grow faster than the endothelial cells that make up the blood vessels, resulting in areas of hypoxia in the tumor. Folkman (1989) *J. Natl. Cancer Inst.* 82:4-6; and Kallinowski (1996) *The Cancer J.* 9:37-40. An important mediator of hypoxic responses is the transcriptional complex HIF-1, or hypoxia inducible factor-1, which interacts with a hypoxia-responsive element (HRE) in the regulatory regions of several genes, including vascular endothelial growth factor, and several genes encoding glycolytic enzymes, including enolase-

1. Murine HRE sequences have been identified and characterized. Firth et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:6496-6500. An HRE from a rat enolase-1 promoter is described in Jiang et al. (1997) *Cancer Res.* 57:5328-5335. An HRE from a rat enolase-1 promoter is depicted in Figure 2 and given as SEQ ID NO:1.

5 Accordingly, in one embodiment, an adenovirus vector comprises an adenovirus gene, preferably an adenoviral gene essential for replication, under transcriptional control of a cell status-specific TRE comprising an HRE. In one embodiment, the cell status-specific TRE comprises the HRE depicted in Figure 2 and SEQ ID NO:1.

10 Other cell status-specific TREs include heat-inducible (i.e., heat shock) promoters, and promoters responsive to radiation exposure, including ionizing radiation and UV radiation. For example, the promoter region of the early growth response-1 (Egr-1) gene contains an element(s) inducible by ionizing radiation. Hallahan et al. (1995) *Nat. Med.* 1:786-791; and Tsai-Morris et al. (1988) *Nucl. Acids. Res.* 16:8835-8846. Heat-inducible promoters, including heat-inducible elements, have been described. See, for example Welsh (1990) in "Stress Proteins in Biology and Medicine", Morimoto, Tissieres, and Georgopoulos, eds. Cold Spring Harbor Laboratory Press; and Perisic et al. (1989) *Cell* 59:797-806. Accordingly, in some embodiments, the cell status-specific TRE comprises an element(s) responsive to ionizing radiation. In one embodiment, this TRE comprises a 5' flanking sequence of an Egr-1 gene. In other embodiments, the cell status-specific TRE comprises a heat shock responsive, or heat-inducible, element.

15 A cell status-specific TRE can also comprise multimers. For example, an HRE can comprise a tandem series of at least two, at least three, at least four, or at least five hypoxia-responsive elements. These multimers may also contain heterologous promoter and/or enhancer sequences.

20 A cell status-specific TRE may or may not lack a silencer. The presence of a silencer (i.e., a negative regulatory element) may assist in shutting off transcription (and thus replication) in non-permissive cells (i.e., cell in a normal cell state). Thus, presence of a silencer may confer enhanced cell status-specific replication by more effectively preventing adenoviral vector replication in non-target cells. Alternatively, lack of a silencer may assist in

effecting replication in target cells, thus conferring enhanced cell status-specific replication due to more effective replication in target cells.

In other embodiments, the adenoviral vector comprises an adenoviral gene essential for adenoviral replication under control of a first cell status-specific TRE, and a second adenoviral gene essential for adenoviral replication under control of a second cell status-specific TRE.

5 The first and the second cell status-specific TREs may or may not be identical, and may or may not be substantially identical to one another. By "substantially identical" is meant a requisite degree of sequence identity between the two TREs. The degree of sequence identity between these TREs is at least about 80%, preferably at least about 85%, more preferably at

10 least about 90%, even more preferably at least about 95%, even more preferably at least about 98%, and most preferably 100%. Sequence identity can be determined by a sequence

comparison using, i.e., sequence alignment programs that are known in the art, such as those described in *Current Protocols in Molecular Biology* (F.M. Ausubel et al., eds., 1987)

Supplement 30, section 7.7.18, Table 7.7.1 A preferred alignment program is ALIGN Plus
15 (Scientific and Educational Software, Pennsylvania), preferably using default parameters.

Alternatively, hybridization under stringent conditions can also indicate degree of sequence identity. Stringent conditions are known in the art; an example of a stringent condition is 80°C (or higher temperature) and 6 X SSC (or less concentrated SSC). Other hybridization conditions and parameters (in order of increasing stringency) are: incubation temperatures of
20 25°C, 37°C, 50°C, and 68°C; buffer concentrations of 10 X SSC, 6 X SSC, 1 X SSC, 0.1 X SSC (where 1 X SSC is 0.15 M NaCl and 15 mM citrate buffer) and their equivalents using other buffer systems; formamide concentrations of 0%, 25%, 50%, and 75%; incubation times from about 24 hours about 5 minutes; 1, 2, or more washing steps; wash incubation times of 1, 2, or 15 minutes; and wash solutions of 6 X SSC, 1 X SSC, 0.1 X SSC, or deionized water.

25 Adenoviral constructs in which the first and second cell status-specific TREs are identical or substantially identical, particularly if these TREs control transcription of early genes (such as E1A and E1B), may display an instability which may be desirable in certain contexts, such as when an automatic "self-destruction" property can shut down the virus, thereby controlling the degree of propagation. Accordingly, in some embodiments, the first and second cell status-specific TRE, or the first and second TRE (one of which is a cell-status-

specific TRE) are sufficiently identical to confer instability when compared to two TREs which are less identical with respect to each other (i.e., have more sequence divergence or dissimilarity). Preferred embodiments are those in which the two TREs control E1A and E1B respectively. “Instability” means that the structural integrity of the adenoviral vectors is not preserved as the virus replicates in cells, and can be measured using standard methods in the art, such as Southern analysis. In other embodiments, the first and second TREs are sufficiently divergent and/or placed in the vector such that the vector is stable (i.e., the structural integrity of the adenoviral vector is preserved).

In other embodiments, the adenoviral vector comprises an adenoviral gene essential for adenoviral replication under control of a first cell status-specific TRE, and a transgene under control of a second cell status-specific TRE. The first and the second cell status-specific TREs may or may not be substantially identical to one another.

In some embodiments, a cell status-specific TRE can be juxtaposed with another TRE, such as a different cell status-specific TRE, or, alternatively, a cell type-specific TRE. “Juxtaposed” means a cell status-specific TRE and the second TRE transcriptionally control the same gene, or at least are proximate with respect to the same gene. For these embodiments, the cell status-specific TRE and the second TRE may be in any of a number of configurations, including, but not limited to, (a) next to each other (i.e., abutting); (b) both 5' to the gene that is transcriptionally controlled (i.e., may have intervening sequences between them); (c) one TRE 5' and the other TRE 3' to the gene. For example, as described in Example 1 and shown in Figure 1, a cell type-specific TRE can be juxtaposed with a cell status-specific TRE to control transcription of an operably linked adenoviral gene. Such “composite” TREs can be used to confer both cell status- and cell type-specific expression of an operably linked polynucleotide, and thus may confer significantly greater specificity and/or efficacy. Examples of cell type-specific TREs are provided below. Alternatively, “composite” TREs can be used to confer different, and possibly synergistic, cell status specificity. For example, a composite TRE could confer specificity to hypoxia and heat shock.

Example 1 provides a description of an adenovirus construct in which a composite TRE upstream of E1A consisting of an HRE and a prostate-specific TRE, PSA-TRE (which consists of enhancer sequences -5322 to -3738 fused to PSA promoter sequence -541 to +12; see U.S.

Pat. Nos. 5,871,726; 5,648,478). Accordingly, in some embodiments, the invention provides an adenovirus vector comprising an adenovirus gene essential for replication, preferably an early gene, preferably E1A or E1B, under transcriptional control of a TRE comprising an HRE (preferably comprising or consisting of the 67-base fragment depicted in SEQ ID NO:1) and a prostate cell specific TRE, preferably comprising a PSA enhancer (preferably -5322 to -3738; or about 503 to about 2086 of SEQ ID NO:3 (bases about 503 to about 2086 of Figure 4), and a promoter, preferably comprising a PSA enhancer and a PSA promoter (about 5285 to about 5836 of SEQ ID NO:3).

As is readily appreciated by one skilled in the art, a cell status-specific TRE is a polynucleotide sequence, and, as such, can exhibit function over a variety of sequence permutations. Methods of nucleotide substitution, addition, and deletion are known in the art, and readily available functional assays (such as the CAT or luciferase reporter gene assay) allow one of ordinary skill to determine whether a sequence variant exhibits requisite cell status-specific transcription function. Hence, the invention also includes functionally-preserved variants of the nucleic acid sequences disclosed herein, which include nucleic acid substitutions, additions, and/or deletions. While not wishing to be bound by a single theory, the inventors note that it is possible that certain modifications will result in modulated resultant expression levels, including enhanced expression levels. Achievement of modulated resultant expression levels, preferably enhanced expression levels, may be especially desirable in the case of certain, more aggressive forms of cancer, or when a more rapid and/or aggressive pattern of cell killing is warranted (due to an immunocompromised condition of the individual, for example).

As an example of how cell status-specific TRE activity can be determined, a polynucleotide sequence or set of such sequences can be generated using methods known in the art, such as chemical synthesis, site-directed mutagenesis, PCR, and/or recombinant methods. The sequence(s) to be tested is inserted into a vector containing an appropriate reporter gene, including, but not limited to, chloramphenicol acetyl transferase (CAT), β -galactosidase (encoded by the lacZ gene), luciferase (encoded by the luc gene), green fluorescent protein, alkaline phosphatase, and horse radish peroxidase. Such vectors and assays are readily available, from, inter alia, commercial sources. Plasmids thus constructed

are transfected into a suitable host cell to test for expression of the reporter gene as controlled by the putative cell status-specific TRE using transfection methods known in the art, such as calcium phosphate precipitation, electroporation, liposomes (lipofection), and DEAE-dextran. Suitable host cells include any cell type, including but not limited to, Hep3B, Hep G2, HuH7,
5 HuH1/Cl2, LNCaP, HBL-100, Chang liver cells, MCF-7, HLF, HLE, 3T3, HUVEC, and HeLa. Host cells transfected with the TRE-reporter gene construct to be tested are subjected to conditions which result in a change in cell status (for example, one which result in an aberrant physiological state). The same cells not subjected to these conditions, i.e., which are under normal physiological conditions and therefore in a normal physiological state, serve as
10 controls. Results are obtained by measuring the level of expression of the reporter gene using standard assays. Comparison of expression between cells in a particular state and control indicates presence or absence of transcriptional activation. "Transcriptional activation" has been defined above.

Comparisons between or among various cell status-specific TREs can be assessed, for
15 example, by measuring and comparing levels of expression within a single cell line under normal and aberrant physiological conditions. These comparisons may also be made by measuring and comparing levels of expression within a single cell line subjected to reversible environmental conditions (such as heat) and cells not subjected to such conditions. It is understood that absolute transcriptional activity of an cell status-specific TRE will depend on
20 several factors, such as the nature of the target cell, delivery mode and form of the cell status-specific TRE, and the coding sequence that is to be selectively transcriptionally activated. To compensate for various plasmid sizes used, activities can be expressed as relative activity per mole of transfected plasmid. Alternatively, the level of transcription (i.e., mRNA) can be measured using standard Northern analysis and hybridization techniques. Levels of
25 transfection (i.e., transfection efficiencies) are measured by co-transfected a plasmid encoding a different reporter gene under control of a different TRE, such as the cytomegalovirus (CMV) immediate early promoter. This analysis can also indicate negative regulatory regions, i.e., silencers.

As an example of how hypoxia induction can be measured, one can use an assay such
30 as that described in Jiang et al. (1997) *Cancer Research* 57:5328-5335 or Dachs et al. (1997)

Nature Med. 3:515-520. For example, a construct comprising a putative HRE, or multiple tandem copies thereof, together with a minimal promoter element, operably linked and controlling transcription of a polynucleotide which encodes a protein which is detectable or can be used to give a detectable signal, is introduced into host cells. The host cells are then subjected to conditions of normoxia (e.g., 20% O₂), and varying degrees of hypoxia, such as 5% 2%, 1%, 0.1%, or less, O₂. The expression product of the operably linked polynucleotide (reporter gene) is then measured.

Alternatively a putative cell status-specific TRE can be assessed for its ability to confer adenoviral replication preference for cells exhibiting the requisite physiological state, such as heat or ionizing radiation. For this assay, constructs containing an adenovirus gene essential to replication operably linked to a putative cell status-specific TRE are transfected into cells which exhibit the requisite physiological state. Viral replication in those cells is compared, for example, to viral replication by the construct in cells under normal physiological conditions (i.e., not exhibiting the requisite physiological state).

Any of the various serotypes of adenovirus can be used, such as Ad2, Ad5, Ad12 and Ad40. For purposes of illustration, serotype Ad5 will be exemplified herein.

When a cell status-specific TRE is used with an adenovirus gene that is essential for propagation replication competence is preferentially achievable in the target cell expressing cell status. Preferably, the gene is an early gene, such as E1A, E1B, E2, or E4. (E3 is not essential for viral replication.) More preferably, the early gene under cell status-TRE control is E1A and/or E1B. More than one early gene can be placed under control of an cell status-specific TRE. Example 1 provides a more detailed description of such constructs.

The E1A gene is expressed immediately after viral infection (0-2 hours) and before any other viral genes. E1A protein acts as a *trans*-acting positive-acting transcriptional regulatory factor, and is required for the expression of the other early viral genes E1B, E2, E3, E4, and the promoter-proximal major late genes. Despite the nomenclature, the promoter proximal genes driven by the major late promoter are expressed during early times after Ad5 infection. Flint (1982) *Biochem. Biophys. Acta* 651:175-208; Flint (1986) *Advances Virus Research* 31:169-228; Grand (1987) *Biochem. J.* 241:25-38. In the absence of a functional E1A gene, viral infection does not proceed, because the gene products necessary for viral DNA

replication are not produced. Nevins (1989) *Adv. Virus Res.* 31:35–81. The transcription start site of Ad5 E1A is at 498 and the ATG start site of the E1A protein is at 560 in the virus genome.

The E1B protein functions *in trans* and is necessary for transport of late mRNA from the nucleus to the cytoplasm. Defects in E1B expression result in poor expression of late viral proteins and an inability to shut off host cell protein synthesis. The promoter of E1B has been implicated as the defining element of difference in the host range of Ad40 and Ad5: clinically Ad40 is an enterovirus, whereas Ad5 causes acute conjunctivitis. Bailey, Mackay et al. (1993) *Virology* 193:631; Bailey et al. (1994) *Virology* 202:695-706). The E1B promoter of Ad5 consists of a single high-affinity recognition site for SpI and a TATA box.

The E2 region of adenovirus codes for proteins related to replication of the adenoviral genome, including the 72 kDa DNA-binding protein, the 80 kD precursor terminal protein and the viral DNA polymerase. The E2 region of Ad5 is transcribed in a rightward orientation from two promoters, termed E2 early and E2 late, mapping at 76.0 and 72.0 map units, respectively. While the E2 late promoter is transiently active during late stages of infection and is independent of the E1A transactivator protein, the E2 early promoter is crucial during the early phases of viral replication.

The E2 late promoter overlaps with the coding sequences of a gene encoded by the counterstrand and is therefore not amenable to genetic manipulation. However, the E2 early promoter overlaps only for a few base pairs with sequences coding for a 33 kD protein on the counterstrand. Notably, the SpI restriction site (Ad5 position 27082) is part of the stop codon for the above mentioned 33 kD protein and conveniently separates the major E2 early transcription initiation site and TATA-binding protein site from the upstream transcription factor binding sites E2F and ATF. Therefore, insertion of a cell status-TRE having SpI ends into the SpI site in the + strand would disrupt the endogenous E2 early promoter of Ad5 and should allow cell status-restricted expression of E2 transcripts.

The E4 gene has a number of transcription products. The E4 region codes for two polypeptides which are responsible for stimulating the replication of viral genomic DNA and for stimulating late gene expression. The protein products of open reading frames (ORFS) 3 and 6 can both perform these functions by binding the 55kD protein from E1B and

heterodimers of E2F-1 and DP-1. The ORF 6 protein requires interaction with the E1B 55kD protein for activity while the ORF 3 protein does not. In the absence of functional protein from ORF 3 and ORF 6, plaques are produced with an efficiency less than 10^{-6} that of wild type virus. To further restrict viral replication to cells exhibiting a requisite physiological condition or state, E4 ORFs 1-3 can be deleted, making viral DNA replication and late gene synthesis dependent on E4 ORF 6 protein. By combining such a mutant with sequences in which the E1B region is regulated by a cell status-specific TRE, a virus can be obtained in which both the E1B function and E4 function are dependent on a cell status-specific TRE driving E1B.

The major late genes relevant to the subject invention are genes L1, L2, L3, L4, and L5 which encode proteins of the adenovirus virion. All of these genes (typically coding for structural proteins) are probably required for adenoviral replication. The late genes are all under the control of the major late promoter (MLP), which is located in Ad5 at +5986 to +6048.

In addition to conferring selective cytotoxic and/or cytolytic activity by virtue of preferential replication competence in cells exhibiting a requisite physiological state (for example, an aberrant physiological state such as low oxygen conditions), the adenovirus vectors of this invention can further include a heterologous gene (transgene) under the control of a cell status-specific TRE. In this way, various genetic capabilities may be introduced into target cells, particularly cancer cells. For example, in certain instances, it may be desirable to enhance the degree and/or rate of cytotoxic activity, due to, for example, the relatively refractory nature or particular aggressiveness of the cancerous target cell. This could be accomplished by coupling the cell status-specific replicative cytotoxic activity with cell-specific expression of, for example, HSV-tk and/or cytosine deaminase (cd), which renders cells capable of metabolizing 5-fluorocytosine (5-FC) to the chemotherapeutic agent 5-fluorouracil (5-FU). Using these types of transgenes may also confer a bystander effect.

Other desirable transgenes that may be introduced via an adenovirus vector(s) include genes encoding cytotoxic proteins, such as the A chains of diphtheria toxin, ricin or abrin (Palmiter et al. (1987) *Cell* 50: 435; Maxwell et al. (1987) *Mol. Cell. Biol.* 7: 1576; Behringher et al. (1988) *Genes Dev.* 2: 453; Messing et al. (1992) *Neuron* 8: 507; Piatak et al. (1988) *J.*

Biol. Chem. 263: 4937; Lamb et al. (1985) *Eur. J. Biochem.* 148: 265; Frankel et al. (1989) *Mol. Cell. Biol.* 9: 415), genes encoding a factor capable of initiating apoptosis, sequences encoding antisense transcripts or ribozymes, which among other capabilities may be directed to mRNAs encoding proteins essential for proliferation, such as structural proteins, or 5 transcription factors; viral or other pathogenic proteins, where the pathogen proliferates intracellularly; genes that encode an engineered cytoplasmic variant of a nuclease (e.g. RNase A) or protease (e.g. awsin, papain, proteinase K, carboxypeptidase, etc.), or encode the Fas gene, and the like. Other genes of interest include cytokines, antigens, transmembrane 10 proteins, and the like, such as IL-1, -2, -6, -12, GM-CSF, G-CSF, M-CSF, IFN- α , - β , - γ , TNF- α , - β , TGF- α , - β , NGF, and the like. The positive effector genes could be used in an earlier phase, followed by cytotoxic activity due to replication.

In one embodiment, the adenovirus death protein (ADP), encoded within the E3 region, is maintained in the adenovirus vector. The ADP gene, under control of the major late promoter (MLP), appears to code for a protein (ADP) that is important in expediting host cell 15 lysis. Tollefson et al. (1996) *J. Virol.* 70(4):2296; Tollefson et al. (1992) *J. Virol.* 66(6):3633. Thus, adenoviral vectors containing the ADP gene may render the adenoviral vector more potent, making possible more effective treatment and/or a lower dosage requirement.

Accordingly, the invention provides an adenoviral vector as described herein that further includes a polynucleotide sequence encoding an ADP. A DNA sequence encoding an 20 ADP and the amino acid sequence of an ADP are depicted Figure 9. Briefly, an ADP coding sequence is obtained preferably from Ad2 (since this is the strain in which ADP has been more fully characterized) using techniques known in the art, such as PCR. Preferably, the Y leader (which is an important sequence for correct expression of late genes) is also obtained and ligated to the ADP coding sequence. The ADP coding sequence (with or without the Y leader) 25 can then be introduced into the adenoviral genome, for example, in the E3 region (where the ADP coding sequence will be driven by the MLP). The ADP coding sequence could also be inserted in other locations of the adenovirus genome, such as the E4 region. Alternatively, the ADP coding sequence could be operably linked to a heterologous promoter (with or without enhancer(s)), including, but not limited to, another viral promoter, a cell status-specific TRE

such as a hypoxia responsive element, or a cell type-specific TRE such as those derived from carcinoembryonic antigen (CEA), mucin, and rat probasin genes.

Adenoviral vectors of the invention further comprising a cell type specific element

In addition to conferring selective cytotoxic and/or cytolytic activity by virtue of
5 preferential replication competence and/or by preferential transcription of a gene encoding a cytotoxic factor in cells exhibiting a requisite physiological state, the adenovirus vectors of this invention can further include an adenovirus gene and/or a heterologous gene (transgene) under the control of a cell type-specific TRE. In this way, cytotoxicity is further limited to a particular cell type.

10 For example, TREs that function preferentially in prostate cells include, but are not limited to, TREs derived from the prostate-specific antigen gene (*PSA*-TRE) (U.S. Patent No. 5,648,478), the glandular kallikrein-1 gene (from the human gene, *hKLK2*-TRE), and the probasin gene (*PB*-TRE) (International Patent Application No. PCT/US98/04132). All three of these genes are preferentially expressed in prostate cells and the expression is androgen-inducible. Generally, expression of genes responsive to androgen induction requires the presence of an androgen receptor (AR).

15 PSA is synthesized exclusively by normal, hyperplastic, and malignant prostatic epithelia; hence, its tissue-specific expression has made it an excellent biomarker for benign prostatic hyperplasia (BPH) and prostatic carcinoma (CaP). Normal serum levels of PSA are typically below 5 ng/ml, with elevated levels indicative of BPH or CaP. Lundwall et al. (1987) *FEBS Lett.* 214: 317; Lundwall (1989) *Biochem. Biophys. Res. Comm.* 161: 1151; and Riegmann et al. (1991) *Molec. Endocrin.* 5: 1921.

20 The region of the *PSA* gene that is used to provide cell specificity dependent upon androgens, particular in prostate cells, involves approximately 6.0 kilobases. Schuur et al. (1996) *J. Biol. Chem.* 271:7043-7051. An enhancer region of approximately 1.5 kb in humans is located between nt -5322 and nt -3738, relative to the transcription start site of the *PSA* gene. The *PSA* promoter consists of the sequence from about nt -540 to nt +12 relative to the transcription start site. Juxtapositioning of these two genetic elements yield a fully functional, minimal prostate-specific enhancer/promoter (PSE) TRE. Other portions of the approximately

6.0 kb region of the *PSA* gene can be used in the present invention, as long as requisite functionality is maintained. In Example 1, adenoviral vector CN796 is described which comprises a composite TRE comprising an HRE and a PSA-TRE, the PSA-TRE comprising a PSA enhancer from -5322 to -3738 fused to a PSA promoter from -541 to +12. This PSA-TRE is derived from adenoviral vector CN706. Rodriguez et al. (1997) *Cancer Research* 57:2559-2563. Accordingly, in one embodiment an adenoviral vector comprises an adenovirus E1A gene under transcriptional control of a composite TRE comprising the cell status-specific TRE, HRE, and a cell type-specific TRE, a PSA-TRE.

The *PSE* and *PSA* TRE used in the present invention are derived from sequences depicted in Figure 4 (SEQ ID NO:3). The enhancer element is nucleotides about 503 to about 2086 of Figure 4 (SEQ ID NO:3). The promoter is nucleotides about 5285 to about 5836 of Figure 4 (SEQ ID NO:3). Accordingly, in some embodiments, the composite TRE comprises an HRE comprising SEQ ID NO:1 and a PSA-TRE comprises nucleotides about 503 to about 2086 of SEQ ID NO:3. In other embodiments, the composite TRE comprises an HRE comprising SEQ ID NO:1 and a PSA-TRE comprises nucleotides about 503 to about 2086 of SEQ ID NO:3 and nucleotides about 5285 to about 5836 of SEQ ID NO:3. As described above, these composite (HRE/PSA) TREs may be operably linked to an adenovirus gene essential for replication, especially an early gene such as E1A or E1B. Example 1 describes such a construct.

In the present invention, replication-competent adenovirus vectors comprising a cell status-specific TRE and a cell type-specific TRE may employ cell type-specific TREs that are preferentially functional in particular tumor cells. Non-limiting examples of tumor cell-specific TREs, and non-limiting examples of respective potential target cells, include TREs from the following genes: α -fetoprotein (*AFP*) (liver cancer), mucin-like glycoprotein DF3 (*MUC1*) (breast carcinoma), carcinoembryonic antigen (*CEA*) (colorectal, gastric, pancreatic, breast, and lung cancers), plasminogen activator urokinase (*uPA*) and its receptor gene (breast, colon, and liver cancers), *HER-2/neu* (*c-erbB2/neu*) (breast, ovarian, stomach, and lung cancers).

Other cell type-specific TREs may be derived from the following exemplary genes (cell type in which the TREs are specifically functional are in parentheses): vascular endothelial growth factor receptor (endothelium), albumin (liver), factor VII (liver), fatty acid synthase (liver), von Willebrand factor (brain endothelium), alpha-actin and myosin heavy chain (both in smooth muscle), synthetase I (small intestine), Na-K-Cl transporter (kidney). Additional 5 cell type-specific TREs are known in the art.

10 AFP is an oncofetal protein, the expression of which is primarily restricted to developing tissues of endodermal origin (yolk sac, fetal liver, and gut), although the level of its expression varies greatly depending on the tissue and the developmental stage. AFP is of clinical interest because the serum concentration of AFP is elevated in a majority of hepatoma patients, with high levels of AFP found in patients with advanced disease. The serum AFP levels in patients appear to be regulated by AFP expression in hepatocellular carcinoma but not in surrounding normal liver. Thus, the AFP gene appears to be regulated to hepatoma cell-specific expression.

15 Cell type-specific TREs from the *AFP* gene have been identified. For example, the cloning and characterization of human AFP-specific enhancer activity is described in Watanabe et al. (1987) *J. Biol. Chem.* 262:4812-4818. The entire 5' *AFP* flanking region (containing the promoter, putative silencer, and enhancer elements) is contained within approximately 5 kb upstream from the transcription start site.

20 The *AFP* enhancer region in human is located between about nt -3954 and about nt -3335, relative to the transcription start site of the *AFP* gene. The human *AFP* promoter encompasses a region from about nt -174 to about nt +29. Juxtapositioning of these two genetic elements yields a fully functional *AFP*-TRE. Ido et al. (1995) describe a 259 bp promoter fragment (nt -230 to nt +29) that is specific for HCC. *Cancer Res.* 55:3105-3109.
25 The *AFP* enhancer contains two regions, denoted A and B, located between nt -3954 and nt -3335 relative to the transcription start site. The promoter region contains typical TATA and CAAT boxes. Preferably, the *AFP*-TRE contains at least one enhancer region. More preferably, the *AFP*-TRE contains both enhancer regions.

30 Suitable target cells for adenoviral vectors containing *AFP*-TREs are any cell type that allow an *AFP*-TRE to function. Preferred are cells that express, or produce, AFP, including,

but not limited to, tumor cells expressing AFP. Examples of such cells are hepatocellular carcinoma cells, gonadal and other germ cell tumors (especially endodermal sinus tumors), brain tumor cells, ovarian tumor cells, acinar cell carcinoma of the pancreas (Kawamoto et al. (1992) *Hepatogastroenterology* 39:282–286), primary gall bladder tumor (Katsuragi et al. 5 (1989) *Rinsko Hoshasen* 34:371–374), uterine endometrial adenocarcinoma cells (Koyama et al. (1996) *Jpn. J. Cancer Res.* 87:612-617), and any metastases of the foregoing (which can occur in lung, adrenal gland, bone marrow, and/or spleen). In some cases, metastatic disease to the liver from certain pancreatic and stomach cancers produce AFP. Especially preferred are hepatocellular carcinoma cells and any of their metastases. AFP production can be measured using assays standard in the art, such as RIA, ELISA or Western blots (immunoassays) to determine levels of AFP protein production or Northern blots to determine levels of AFP mRNA production. Alternatively, such cells can be identified and/or characterized by their ability to activate transcriptionally an *AFP*-TRE (i.e., allow an *AFP*-TRE to function).

10 15 The protein urokinase plasminogen activator (uPA) and its cell surface receptor, urokinase plasminogen activator receptor (uPAR), are expressed in many of the most frequently occurring neoplasia and appear to represent important proteins in cancer metastasis. Both proteins are implicated in breast, colon, prostate, liver, renal, lung and ovarian cancer. Transcriptional regulatory elements that regulate uPA and uPAR transcription have been 20 extensively studied. Riccio et al. (1985) *Nucleic Acids Res.* 13:2759-2771; Cannio et al. (1991) *Nucleic Acids Res.* 19:2303–2308.

25 CEA is a 180,000-Dalton glycoprotein tumor-associated antigen present on endodermally-derived neoplasia of the gastrointestinal tract, such as colorectal, gastric (stomach) and pancreatic cancer, as well as other adenocarcinomas such as breast and lung cancers. CEA is of clinical interest because circulating CEA can be detected in the great majority of patients with CEA-positive tumors. In lung cancer, about 50% of total cases have circulating CEA, with high concentrations of CEA (greater than 20 ng/ml) often detected in adenocarcinomas. Approximately 50% of patients with gastric carcinoma are serologically positive for CEA.

The 5' upstream flanking sequence of the *CEA* gene has been shown to confer cell-specific activity. The *CEA* promoter region, approximately the first 424 nucleotides upstream of the translational start site in the 5' flanking region of the gene, was shown to confer cell-specific activity when the region provided higher promoter activity in CEA-producing cells than in non-producing HeLa cells.. Schrewe et al. (1990) *Mol. Cell. Biol.* 10:2738-2748. In addition, cell-specific enhancer regions have been found. WO/95/14100. The entire 5' *CEA* flanking region (containing the promoter, putative silencer, and enhancer elements) appears to be contained within approximately 14.5 kb upstream from the transcription start site. Richards et al. (1995); WO 95/14100. Further characterization of the 5' flanking region of the *CEA* gene by Richards et al. (1995) indicated two upstream regions, -13.6 to -10.7 kb or -6.1 to -4.0 kb, when linked to the multimerized promoter resulted in high-level and selective expression of a reporter construct in CEA-producing LoVo and SW1463 cells. Richards et al. (1995) also localized the promoter region to nt -90 and nt +69 relative to the transcriptional start site, with region nt -41 to nt -18 as essential for expression. WO95/14100 describes a series of 5' flanking *CEA* fragments which confer cell-specific activity, such as about nt -299 to about nt +69; about nt -90 to about nt +69; nt -14,500 to nt -10,600; nt -13,600 to nt -10,600, nt -6100 to nt -3800. In addition, cell specific transcription activity is conferred on an operably linked gene by the *CEA* fragment from nt -402 to nt +69, depicted in (SEQ ID NO:6). Any *CEA*-TREs used in the present invention are derived from mammalian cells, including but not limited to, human cells. Thus, any of the *CEA*-TREs may be used in the invention as long as requisite desired functionality is displayed in the adenovirus vector. The cloning and characterization of *CEA* sequences have been described in the literature and are thus made available for practice of this invention and need not be described in detail herein.

The protein product of the *MUC1* gene (known as mucin or MUC1 protein; episialin; polymorphic epithelial mucin or PEM; EMA; DF3 antigen; NPGP; PAS-O; or CA15.3 antigen) is normally expressed mainly at the apical surface of epithelial cells lining the glands or ducts of the stomach, pancreas, lungs, trachea, kidney, uterus, salivary glands, and mammary glands. Zotter et al. (1988) *Cancer Rev.* 11-12: 55-101; and Girling et al. (1989) *Int. J. Cancer* 43: 1072-1076. However, mucin is overexpressed in 75-90% of human breast carcinomas. Kufe et al. (1984) *Hybridoma* 3: 223-232. For reviews, see Hilkens (1988)

Cancer Rev. 11–12: 25–54; and Taylor-Papadimitriou, et al. (1990) *J. Nucl. Med. Allied Sci.* 34: 144–150. Mucin protein expression correlates with the degree of breast tumor differentiation. Lundy et al. (1985) *Breast Cancer Res. Treat.* 5: 269–276. This overexpression appears to be controlled at the transcriptional level.

5 Overexpression of the *MUC1* gene in human breast carcinoma cells MCF-7 and ZR-75-1 appears to be regulated at the transcriptional level. Kufe et al. (1984); Kovarik (1993) *J. Biol. Chem.* 268:9917–9926; and Abe et al. (1990) *J. Cell. Physiol.* 143: 226–231. The regulatory sequences of the *MUC1* gene have been cloned, including the approximately 0.9 kb upstream of the transcription start site which contains a TRE that appears to be involved in 10 cell-specific transcription. Abe et al. (1993) *Proc. Natl. Acad. Sci. USA* 90: 282–286; Kovarik et al. (1993); and Kovarik et al. (1996) *J. Biol. Chem.* 271:18140–18147.

15 Any *MUC1*-TREs used in the present invention are derived from mammalian cells, including but not limited to, human cells. Preferably, the *MUC1*-TRE is human. In one embodiment, the *MUC1*-TRE may contain the entire 0.9 kb 5' flanking sequence of the *MUC1* gene. In other embodiments, the *MUC1*-TREs comprise the following sequences (relative to 20 the transcription start site of the *MUC1* gene): about nt -725 to about nt +31, nt -743 to about nt +33, nt -750 to about nt +33, and nt -598 to about nt +485 (operably-linked to a promoter).

The *c-erbB2/neu* gene (*HER-2/neu* or *HER*) is a transforming gene that encodes a 185 kD epidermal growth factor receptor-related transmembrane glycoprotein. In humans, the *c-erbB2/neu* protein is expressed during fetal development, however, in adults, the protein is weakly detectable (by immunohistochemistry) in the epithelium of many normal tissues. Amplification and/or over-expression of the *c-erbB2/neu* gene has been associated with many 25 human cancers, including breast, ovarian, uterine, prostate, stomach and lung cancers. The clinical consequences of the *c-erbB2/neu* protein over-expression have been best studied in breast and ovarian cancer. *c-erbB2/neu* protein over-expression occurs in 20 to 40% of intraductal carcinomas of the breast and 30% of ovarian cancers, and is associated with a poor prognosis in subcategories of both diseases. Human, rat and mouse *c-erbB2/neu* TREs have been identified and shown to confer *c-erbB2/neu* expressing cell specific activity. Tal et al. (1987) *Mol. Cell. Biol.* 7:2597–2601; Hudson et al. (1990) *J. Biol. Chem.* 265:4389–4393;

Grooteclaes et al. (1994) *Cancer Res.* 54:4193–4199; Ishii et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:4374–4378; Scott et al. (1994) *J. Biol. Chem.* 269:19848–19858.

The cell type-specific TREs listed above are provided as non-limiting examples of TREs that would function in the instant invention. Additional cell-specific TREs are known in the art, as are methods to identify and test cell specificity of suspected TREs.

5

Using the adenoviral vectors of the invention

The adenoviral vectors can be used in a variety of forms, including, but not limited to, naked polynucleotide (usually DNA) constructs; polynucleotide constructs complexed with agents to facilitate entry into cells, such as cationic liposomes or other cationic compounds such as polylysine; packaged into infectious adenovirus particles (which may render the adenoviral vector(s) more immunogenic); packaged into other particulate viral forms such as HSV or AAV; complexed with agents (such as PEG) to enhance or dampen an immune response; complexed with agents that facilitate *in vivo* transfection, such as DOTMA™, DOTAP™, and polyamines. Thus, the invention also provides an adenovirus capable of replicating preferentially in cell status-producing cells. “Replicating preferentially” means that the adenovirus replicates more in cell exhibiting a requisite physiological state than a cell not exhibiting that state. Preferably, the adenovirus replicates at least about 2-fold higher, preferably at least about 5-fold higher, more preferably at least about 10-fold higher, still more preferably at least about 50-fold higher, even more preferably at least about 100-fold higher, still more preferably at least about 400-fold to about 500-fold higher, still more preferably at least about 1000-fold higher, most preferably at least about 1×10^6 higher. Most preferably, the adenovirus replicates solely in cells exhibiting a requisite physiological state (that is, does not replicate or replicates at very low levels in cells not exhibiting the requisite physiological state).

10

15

20

25

If an adenoviral vector is packaged into an adenovirus, the adenovirus itself may also be selected to further enhance targeting. For example, adenovirus fibers mediate primary contact with cellular receptor(s) aiding in tropism. See, e.g., Amberg et al. (1997) *Virology* 227:239-244. If a particular subgenus of an adenovirus serotype displayed tropism for a target

cell type and/or reduced affinity for non-target cell types, such subgenus (or subgenera) could be used to further increase cell-specificity of cytotoxicity and/or cytolysis.

The adenoviral vectors may be delivered to the target cell in a variety of ways, including, but not limited to, liposomes, general transfection methods that are well known in the art (such as calcium phosphate precipitation or electroporation), direct injection, and intravenous infusion. The means of delivery will depend in large part on the particular adenoviral vector (including its form) as well as the type and location of the target cells (i.e., whether the cells are *in vitro* or *in vivo*).

If used as a packaged adenovirus, adenovirus vectors may be administered in an appropriate physiologically acceptable carrier at a dose of about 10^4 to about 10^{14} . The multiplicity of infection will generally be in the range of about 0.001 to 100. If administered as a polynucleotide construct (i.e., not packaged as a virus) about 0.01 μ g to about 1000 μ g of an adenoviral vector can be administered. The adenoviral vector(s) may be administered one or more times, depending upon the intended use and the immune response potential of the host, and may also be administered as multiple, simultaneous injections. If an immune response is undesirable, the immune response may be diminished by employing a variety of immunosuppressants, so as to permit repetitive administration, without a strong immune response. If packaged as another viral form, such as HSV, an amount to be administered is based on standard knowledge about that particular virus (which is readily obtainable from, for example, published literature) and can be determined empirically.

Host cells comprising the adenoviral vectors of the invention

The present invention also provides host cells comprising (i.e., transformed with) the adenoviral vectors described herein. Both prokaryotic and eukaryotic host cells can be used as long as sequences requisite for maintenance in that host, such as appropriate replication origin(s), are present. For convenience, selectable markers are also provided. Prokaryotic host cells include bacterial cells, for example, *E. coli* and mycobacteria. Among eukaryotic host cells are yeast, insect, avian, plant and mammalian. Host systems are known in the art and need not be described in detail herein.

Compositions of the invention

The present invention also provides compositions, including pharmaceutical compositions, containing the adenoviral vectors described herein. Such compositions (especially pharmaceutical compositions) are useful for administration *in vivo*, for example, 5 when measuring the degree of transduction and/or effectiveness of cell killing in an individual. Pharmaceutical compositions, comprised an adenoviral vector of this invention in a pharmaceutically acceptable excipient (generally an effective amount of the adenoviral vector), are suitable for systemic administration to individuals in unit dosage forms, sterile parenteral solutions or suspensions, sterile non-parenteral solutions or oral solutions or suspensions, oil in 10 water or water in oil emulsions and the like. Formulations for parenteral and nonparenteral drug delivery are known in the art and are set forth in *Remington's Pharmaceutical Sciences*, 19th Edition, Mack Publishing (1995). Pharmaceutical compositions also include lyophilized and/or reconstituted forms of the adenoviral vectors (including those packaged as a virus, such 15 as adenovirus) of the invention.

Other compositions are used, and are useful for, detection methods described herein. For these compositions, the adenoviral vector usually is suspended in an appropriate solvent or solution, such as a buffer system. Such solvent systems are well known in the art.

Kits of the invention

20 The present invention also encompasses kits containing an adenoviral vector(s) of this invention. These kits can be used for diagnostic and/or monitoring purposes, preferably monitoring. Procedures using these kits can be performed by clinical laboratories, experimental laboratories, medical practitioners, or private individuals. Kits embodied by this invention allow someone to detect the presence of cell status-producing cells in a suitable 25 biological sample, such as biopsy specimens.

The kits of the invention comprise an adenoviral vector described herein in suitable packaging. The kit may optionally provide additional components that are useful in the procedure, including, but not limited to, buffers, developing reagents, labels, reacting surfaces, means for detection, control samples, instructions, and interpretive information.

Preparation of the adenovirus vectors of the invention

The adenovirus vectors of this invention can be prepared using recombinant techniques that are standard in the art. Generally, a cell status-specific TRE is inserted 5' to the adenoviral gene of interest, preferably one or more early genes (although late gene(s) may be used). A cell status-specific TRE can be prepared using oligonucleotide synthesis (if the sequence is known) or recombinant methods (such as PCR and/or restriction enzymes). Convenient restriction sites, either in the natural adeno-DNA sequence or introduced by methods such as oligonucleotide directed mutagenesis and PCR, provide an insertion site for a cell status-specific TRE. Accordingly, convenient restriction sites for annealing (i.e., inserting) a cell status-specific TRE can be engineered onto the 5' and 3' ends of a cell status-specific TRE using standard recombinant methods, such as PCR.

Polynucleotides used for making adenoviral vectors of this invention may be obtained using standard methods in the art, such as chemical synthesis, by recombinant methods, and/or by obtaining the desired sequence(s) from biological sources.

Adenoviral vectors are conveniently prepared by employing two plasmids, one plasmid providing for the left hand region of adenovirus and the other plasmid providing for the right hand region, where the two plasmids share at least about 500 nt of middle region for homologous recombination. In this way, each plasmid, as desired, may be independently manipulated, followed by cotransfection in a competent host, providing complementing genes as appropriate, or the appropriate transcription factors for initiation of transcription from a cell status-specific TRE for propagation of the adenovirus. Plasmids are generally introduced into a suitable host cell such as 293 cells using appropriate means of transduction, such as cationic liposomes. Alternatively, *in vitro* ligation of the right and left-hand portions of the adenovirus genome can also be used to construct recombinant adenovirus derivative containing all the replication-essential portions of adenovirus genome. Berkner et al. (1983) *Nucleic Acid Research* 11: 6003-6020; Bridge et al. (1989) *J. Virol.* 63: 631-638.

For convenience, plasmids are available that provide the necessary portions of adenovirus. Plasmid pXC.1 (McKinnon (1982) *Gene* 19:33-42) contains the wild-type left-hand end of Ad5. pBHG10 (Bett et al. (1994) *Proc. Natl. Acad. Sci USA* 91:8802-8806; Microbix Biosystems Inc., Toronto) provides the right-hand end of Ad5, with a deletion in E3.

The deletion in E3 provides room in the virus to insert a 3 kb cell status-TRE without deleting the endogenous enhancer/promoter. Bett et al. (1994). The gene for E3 is located on the opposite strand from E4 (r-strand). pBHG11 provides an even larger E3 deletion (an additional 0.3 kb is deleted). Bett et al. (1994).

5 For manipulation of the early genes, the transcription start site of Ad5 E1A is at 498 and the ATG start site of the E1A protein is at 560 in the virus genome. This region can be used for insertion of an cell status-specific TRE. A restriction site may be introduced by employing polymerase chain reaction (PCR), where the primer that is employed may be limited to the Ad5 genome, or may involve a portion of the plasmid carrying the Ad5 genomic
10 DNA. For example, where pBR322 is used, the primers may use the EcoRI site in the pBR322 backbone and the XbaI site at 1339 of Ad5. By carrying out the PCR in two steps, where overlapping primers at the center of the region introduce a 30 sequence change resulting in a unique restriction site, one can provide for insertion of heterologous TRE at that site.

15 A similar strategy may also be used for insertion of a heterologous TRE to regulate E1B. The E1B promoter of Ad5 consists of a single high-affinity recognition site for Sp1 and a TATA box. This region extends from 1636 to 1701. By insertion of a heterologous TRE in this region, one can provide for target cell-specific transcription of the E1B gene. By employing the left-hand region modified with a heterologous TRE regulating E1A as the template for introducing a heterologous TRE to regulate E1B, the resulting adenovirus vector
20 will be dependent upon the cell status-specific transcription factors for expression of both E1A and E1B.

25 Similarly, a cell status-specific TRE can be inserted upstream of the E2 gene to make its expression cell status specific. The E2 early promoter, mapping in Ad5 from 27050-27150, consists of a major and a minor transcription initiation site, the latter accounting for about 5% of the E2 transcripts, two non-canonical TATA boxes, two E2F transcription factor binding sites and an ATF transcription factor binding site. For a detailed review of the E2 promoter architecture see Swaminathan et al., *Curr. Topics in Micro. and Imm.* (1995) 199 (part 3):177-194.

30 For E4, one must use the right hand portion of the adenovirus genome. The E4 transcription start site is predominantly at 35609, the TATA box at 35638 and the first

ATG/CTG of ORF 1 is at 35532. Virtanen et al. (1984) *J. Virol.* 51: 822-831. Using any of the above strategies for the other genes, a cell status-specific TRE may be introduced upstream from the transcription start site. For the construction of mutants in the E4 region, the co-transfection and homologous recombination are performed in W162 cells (Weinberg et al. 5 (1983) *Proc. Natl. Acad. Sci.* 80:5383-5386) which provide E4 proteins *in trans* to complement defects in synthesis of these proteins. Alternatively, these constructs can be produced by *in vitro* ligation.

Methods using the adenovirus vectors of the invention

10 The adenoviral vectors of the invention can be used for a wide variety of purposes, which will vary with the desired or intended result. Accordingly, the present invention includes methods using the adenoviral vectors described above.

15 In one embodiment, methods are provided for conferring selective cytotoxicity in target cells (i.e., cells exhibiting a requisite physiological state which allows a cell status-specific TRE to function), generally but not necessarily in an individual (preferably human), comprising contacting the cells with an adenovirus vector described herein, such that the adenovirus vector enters the cell. Cytotoxicity can be measured using standard assays in the art, such as dye exclusion, ^3H -thymidine incorporation, and/or lysis.

20 In another embodiment, methods are provided for propagating an adenovirus specific for mammalian cells which allow a cell status-specific TRE to function. These methods entail combining an adenovirus vector with mammalian cells, whereby said adenovirus is propagated.

25 The invention further provides methods of suppressing tumor cell growth, generally but not necessarily in an individual (preferably human), comprising contacting a tumor cell with an adenoviral vector of the invention such that the adenoviral vector enters the tumor cell and exhibits selective cytotoxicity for the tumor cell. Tumor cell growth can be assessed by any means known in the art, including, but not limited to, measuring tumor size, determining whether tumor cells are proliferating using a ^3H -thymidine incorporation assay, or counting tumor cells.

The invention also includes methods for detecting target cells (i.e., cells which permit or induce a cell status-specific TRE to function) in a biological sample. These methods are particularly useful for monitoring the clinical and/or physiological condition of an individual (i.e., mammal), whether in an experimental or clinical setting. For these methods, cells of a 5 biological sample are contacted with an adenovirus vector, and replication of the adenoviral vector is detected. A suitable biological sample is one in which cells exhibiting a requisite physiological (and/or environmental) state, for example, an aberrant physiological state (such as cells in hypoxic conditions and exhibiting a phenotype characteristic of cells in hypoxic conditions, such as expression of HIF-1) may be or are suspected to be present. Generally, in 10 mammals, a suitable clinical sample is one in which cancerous cells exhibiting a requisite physiological state, such as cells within a solid tumor which are under hypoxic conditions, are suspected to be present. Such cells can be obtained, for example, by needle biopsy or other surgical procedure. Cells to be contacted may be treated to promote assay conditions, such as selective enrichment, and/or solubilization. In these methods, target cells can be detected 15 using *in vitro* assays that detect adenoviral proliferation, which are standard in the art. Examples of such standard assays include, but are not limited to, burst assays (which measure virus yield) and plaque assays (which measure infectious particles per cell). Propagation can also be detected by measuring specific adenoviral DNA replication, which are also standard assays.

20 The following examples are provided to illustrate but not limit the invention.

EXAMPLES

EXAMPLE 1

25 ***Adenovirus vector comprising E1A under transcriptional control of a hypoxia responsive element and a PSA-TRE***

General techniques

A human embryonic kidney cell line, 293, efficiently expresses E1A and E1B genes of Ad5 and exhibits a high transfection efficiency with adenovirus DNA. To generate

recombinant adenovirus, 293 cells were co-transfected with one left end Ad5 plasmid and one right end Ad5 plasmid. Homologous recombination generates adenoviruses with the required genetic elements for replication in 293 cells which provide E1A and E1B proteins *in trans* to complement defects in synthesis of these proteins.

5 The plasmids to be combined were co-transfected into 293 cells using cationic liposomes such as Lipofectin (DOTMA:DOPE™, Life Technologies) by combining the two plasmids, then mixing the plasmid DNA solution (10 µg of each plasmid in 500 µl of minimum essential medium (MEM) without serum or other additives) with a four-fold molar excess of liposomes in 200 µl of the same buffer. The DNA-lipid complexes were then placed
10 on the cells and incubated at 37°C, 5% CO₂ for 16 hours. After incubation the medium was changed to MEM with 10% fetal bovine serum and the cells are further incubated at 37°C, 5% CO₂, for 10 days with two changes of medium. At the end of this time the cells and medium were transferred to tubes, freeze-thawed three times, and the lysate was used to infect 293 cells at the proper dilution to detect individual viruses as plaques.

15 Plaques obtained were plaque purified twice, and viruses were characterized for presence of desired sequences by PCR and occasionally by DNA sequencing. For further experimentation, the viruses were purified on a large scale by cesium chloride gradient centrifugation.

Adenovirus vectors in which E1A is under transcriptional control of a cell status-specific TRE

20 An adenovirus vector containing a hypoxia response element (HRE) was generated. CN796, an adenovirus vector in which E1A is under the control of a composite TRE consisting of an HRE and a PSA-TRE, was made by co-transfecting CN515 with pBHG10. CN515 was constructed by inserting a 67 base pair fragment from HRE eno1 (Jiang et al. (1997) *Cancer Research* 57:5328-5335) (SEQ ID NO:1; Figure 2) into CN65 at the BglII site. CN65 is a
25 plasmid containing an enhancer and promoter from the human PSA gene, consisting of an enhancer from -5322 to -3738 fused to a PSA promoter from -541 to +12. This is the PSA-TRE contained within plasmid CN706. Rodriguez et al. (1997) *Cancer Res.* 57:2559-2563.

Virus growth in vitro

Growth selectivity of recombinant adenovirus is analyzed in plaque assays in which a single infectious particle produces a visible plaque by multiple rounds of infection and replication. Virus stocks are diluted to equal pfu/ml, then used to infect monolayers of cells for 1 hour. The inoculum is then removed and the cells are overlayed with semisolid agar containing medium and incubated at 37°C for 10 days. Plaques in the monolayer are then counted and titers of infectious virus on the various cells are calculated. The data are normalized to the titer of CN702 (wild type) on 293 cells.

5

Claims

What is claimed is:

1. An adenovirus vector comprising an adenovirus gene under transcriptional control of a transcriptional regulatory element (TRE) comprising a cell status-specific TRE.
- 5 2. The adenovirus vector of claim 1, wherein the adenovirus gene is essential for viral replication.
3. The adenovirus vector of claim 2, wherein the adenovirus gene is an early gene.
4. The adenovirus vector of claim 2, wherein the adenovirus gene is a late gene.
5. The adenovirus vector of claim 3, wherein the adenovirus early gene is E1A.
- 10 6. The adenovirus vector of claim 3, wherein the adenovirus early gene is E1B.
7. The adenovirus vector of claim 3, wherein the adenovirus early gene is E4.
8. The adenovirus vector of claim 1, wherein the cell status-specific TRE is human.
9. The adenovirus vector of claim 1, wherein the cell status-specific TRE comprises a hypoxia responsive element (HRE).
- 15 10. The adenovirus vector of claim 9, wherein the HRE comprises SEQ ID NO:1.
11. The adenovirus vector of claim 1, wherein the cell status-specific TRE comprises a cell cycle specific element.
12. The adenovirus vector of claim 11, wherein the cell cycle-specific element is from the E2F-1 gene.
- 20 13. The adenovirus vector of claim 1, wherein the cell status-specific TRE comprises a heat-inducible element.

14. The adenovirus vector of claim 1, further comprising a cell type-specific TRE.
15. The adenovirus vector of claim 14, wherein the cell type-specific TRE is prostate cell specific.
16. The adenovirus vector of claim 15, wherein the prostate cell-specific TRE is a *PSA*-TRE.
5
17. The adenovirus vector of claim 1, further comprising a transgene under transcriptional control of a second cell status-specific TRE.
18. An adenovirus vector comprising an adenovirus gene under transcriptional control of a a TRE comprising a cell status-specific TRE and a cell-type specific TRE.
10
- 19 The adenovirus vector of claim 18, wherein the adenovirus gene is an early gene.
20. The adenovirus vector of claim 19, wherein the adenovirus early gene is E1A.
21. The adenovirus vector of claim 20, wherein the cell status-specific TRE comprises an HRE and the cell-type specific TRE is a PSA-TRE.
15
22. The adenovirus vector of claim 21, wherein the HRE comprises SEQ ID NO:1 and the PSA-TRE comprises nucleotides about 503 to about 2086 of SEQ ID NO:3 and nucleotides about 5285 to about 5836 of SEQ ID NO:3.
23. A composition comprising an adenovirus vector of claim 1.
24. The composition of claim 23, further comprising a pharmaceutically acceptable excipient.
20
25. A host cell comprising the adenovirus vector of claim 1.
26. A method of propagating adenovirus specific for cells which allow a cell status-specific TRE to function, said method comprising combining an adenovirus according to claim 1 with the cells, whereby said adenovirus is propagated.

27. A method for conferring selective cytotoxicity on a target cell, said method comprising contacting a cell which allows a cell status-specific TRE to function with an adenovirus vector of claim 1, whereby the vector enters the cell.

5 28. A method for suppressing tumor growth comprising introducing the adenovirus vector of claim 1 into a tumor cell which allows a cell status-specific TRE to function, wherein introduction of the adenovirus vector results in suppression of tumor growth.

CN796




FIGURE 1

FIGURE 2

ccccgagg cagtgcatt gagggctcagg gcgtgcgt gagtcgcaggcagaccggc gggttggcaat gcccggaa

FIGURE 3

FIGURE 4A

aagcttctag ttttctttc ccggtgacat cgtggaaagc actagcatct ctaagcaatg 60
atctgtgaca atattcacag tgtaatgcga tccaggaaac tcaactgagc cttgatgtcc 120
agagattttt gtgtttttt ctgagactga gtctcgctct gtgccaggct ggagtgcagt 180
ggtgcaacct tggctcactg caagctccgc ctccctgggtt cacgccccatc tcctgcctca 240
gcctcctgag tagctgggac tacaggcacc cgccaccacg cctggctaatttttgtat 300
tttagtaga gatggggttt cactgtgttta gccaggatgg tctcagtctc ctgacccctgt 360
gatctgccc ccttggccctc ccaaagtgtc gggatgacag gctgagcca ccgcgcctgg 420
ccgatatacca gagattttt gggggctcc atcacacaga catgttgac: gtcttcatgg 480
ttgacttttta gtatccagcc cctctagaaa tctagctgat atagtgtggc taaaaacctt 540
cagcacaaat cacaccgtta gactatctgg tgtggccaa accttcaggt gaacaaaggg 600
actctaatact ggcaggatata tccaaagcat tagagatgac ctcttgcaaa gaaaaagaaa 660
tggaaaagaa aaagaaaagaa aggaaaaaaaaa gagatgacct ctcaggctct 720
gaggggaaac gcctgaggtc tttgagcaag gtcagtcctc tggcacag tctccctcac 780
agggtcattt tgacgatcaa atgtggtcac gtgtatgagg caccagcaca tgcctggctc 840
tggggagtgc cgtgtaaatg tatgcttgca ctgctgaatg cttggatgt gtcagggatt 900
atcttcagca cttacagatg ctcatctcat cctcacagca tcactatggg atgggttatta 960
ctggcctcat ttgatggaga aagtggctgt ggctcagaaa gggggacca cttagaccagg 1020
gacactctgg atgctgggaa ctccagagac catgaccact caccaactgc agagaaatta 1080
attgtggctt gatgtccctg tcttggagag ggtggaggtg gaccttcact aacctcctac 1140
cttgaccctc tcttttaggg ctcttctga cctccacat ggtacttagga ccccatgtt 1200
ttctgtaccc tcttgactct atgacccca ctgcccactg catccagctg ggtccctcc 1260
tatctctatt cccagctggc cagtgcagtc tcagtgcaca cctgtttgtc agtaactctg 1320
aaggggctga cattttactg acttgcaaac aaataagcta actttccaga gttttgtgaa 1380
tgctggcaga gtccatgaga ctcctgagtc agaggcaag gctttactg ctcacagctt 1440
agcagacagc atgaggttca tggtcacatt agtacacattt gccccccca aatctttag 1500
ggtgaccaga gcagtctagg tggatgtgt gcagaagggg tttgtgccac tggtgagaaa 1560
cctgagatta ggaatcctca atcttataact gggacaactt gcaaaccctgc tcagcccttq 1620
tctctgatga agatattatc ttcatgatct tggattgaaa acagacctac tctggaggaa 1680

FIGURE 4B

catattgtat cgattgcct tgacagtaaa caaatctgtt gtaagagaca ttatctttat 1740
tatctaggac agtaagcaag cctggatctg agagagatat catcttgcaa ggatgcctgc 1800
tttacaaaca tccttgaac aacaatccag aaaaaaaaaag gtgttgcgtt ctttgctcag 1860
aagacacaca gatacgtgac agaaccatgg agaattgcct cccaacgctg ttcagccaga 1920
gccttccacc cttgtctgca ggacagtctc aacgttccac cattaaatac ttcttctatc 1980
acatcctgct tctttatgcc taaccaaggt tctaggtccc gatcgactgt gtctggcagc 2040
actccactgc caaaccaga ataaggcagc gtcaggatc ccgaaggggc atggctgggg 2100
atcagaacctt ctgggttga gtgaggagtg ggtccaccct cttgaatttc aaaggagggaa 2160
gaggctggat gtgaaggta tgggggaggg aaagtgtcag ttccgaactc ttaggtcaat 2220
gagggaggag actggtaagg tcccagctcc cgaggtactg atgtggaaat ggcctaagaa 2280
tctcatatcc tcaggaagaa ggtgctggaa tcctgagggg tagagttctg ggtatattt 2340
tggcttaagg ctcttggcc cctgaaggca gaggctggaa ccattaggtc cagggtttgg 2400
ggtatagta atggatctc ttgattcctc aagagtctga ggatcgaggg ttgcccattc 2460
ttccatcttgc ccacctaatic cttactccac ttgagggtat caccagccct tctagctcca 2520
tgaaggccc ctgggcaagc acaatctgag catgaaagat gccccagagg ccttgggtgt 2580
catecactca tcatccagca tcacactctg agggtgtggc cagcacccatg acgtcatgtt 2640
gctgtgacta tccctgcagc gtgcctctcc agccacctgc caaccgtaga gctgcccattc 2700
ctcctctgtt gggagtggcc tgcattgtgc caggtgtgagg cctagtgtca gacaggagc 2760
ctggaatcat agggatccag gactcaaaag tgctagagaa tggccatatg tcaccatcca 2820
tgaaaatctca agggcttctg ggtggaggc acagggacct gaacttatgg tttccaaagt 2880
ctattgctct cccaaatgtag tctccagat acgaggact gtgcacatcat cagccttattc 2940
tccaccacat cttgtaaaag gactacccag ggcctgtat aacaccatgg tgtgtacagg 3000
agttaggggtt ggaggcacgg actcctgtga ggtcacagcc aagggagcat catcatgggt 3060
ggggaggagg caatggacag gcttgagaac gggatgtgg ttgtatttgg ttttcttgg 3120
ttagataaaag tgctgggtat aggattgaga gtggagttatg aagaccagtt aggtggagg 3180
atcagattgg agttgggtta gataaagtgc tgggtatagg attgagagtg gagttatgaag 3240
accagttagg atggaggatc agattggagt tgggttagag atggggtaaa attgtgctcc 3300
ggatgagttt gggattgaca ctgtggaggt ggtttggat ggcattggctt tggatggaa 3360

FIGURE 4C

atagatttgt tttgatgtt gctcagacat ccttggggat tgaactgggg atgaagctgg 3420
gttgatttt ggaggttagaa gacgttggaa tagctgtcag atttgacagt ggccatgagt 3480
tttggttgtat gggaaatcaa acaatggggg aagacataag ggttggctt ttaggttaag 3540
ttgcgttggg ttgatggggt cggggctgtg tataatgcag ttggattggg ttgtattaaa 3600
ttgggttggg tcaggtttt gttgaggat agttgaggat atgcttgggg acaccggatc 3660
catgaggttc tcactggagt ggagacaaac ttccttcca ggatgaatcc aggaaaggct 3720
taattcacgt gttaggggagg tcaggccact ggctaagtat atccttccac tccagctcta 3780
agatggtctt aaattgtat tatctataatc cacttctgtc tccctcaactg tgcttggagt 3840
ttacctgatc actcaactatc aaacaggaga agattttatc aaattctttt tttttttttt 3900
tttttttga gacagagtct cactctgtt cccaggctgg agtgcagtgg cgcaagtctcg 3960
gctcaactgca acctctgect cccaggtca agtGattctc ctgcctcagc ctccctgagtt 4020
gctgggatta caggcatgca gcaccatgcc cagctaattt ttgtattttt agtagagatg 4080
gggtttcacc aatgtttgcc aggctggct cgaactcctg acctggatgtt ccacctgcct 4140
cagccctcca aagtgttggg attacaggcg tcagccaccg cgcccagcca cttttgtcaa 4200
attcttgaga cacagctcgg gctggatcaa gtgagctact ctggtttat tgaacagctg 4260
aaataaccaa ctttttggaa attgtatgaaa tcttacggag ttaacagtgg aggtaccagg 4320
gctcttaaga gttcccgatt ctcttctgag actacaattt gtgattttgc atgccacattt 4380
aatctttttt tttttttttt taaatcgagg tttcagtctc attctatttc ccaggctgga 4440
gttcaatagc gtgatcacag ctcactgttag ctttgaactc ctggccttaa gagattctcc 4500
tgcttcggtc tcccaatagc taagactaca gtgtccacc accatatcca gataattttt 4560
aaatttttg gggggccggg cacagtggct cacccctgtatcccaacac catgggagggc 4620
tgagatgggt ggatcacgag gtcaggagtt tgagaccgc ctgaccaaca tggtaaact 4680
ctgtctctac taaaaaaaaaaa aaaaatagaa aaattagccg ggcgtgggttgg cacacggcac 4740
ctgtatccc agctactgag gaggctgagg caggagaatc acttgaaccc agaaggcaga 4800
ggttgcaatg agccgagatt gcccactgc actccagcct gggtgacaga gtgagactct 4860
gtctcaaaaa aaaaaaattt tttttttttt tttgttagaga tggatcttgc tttgtttctc 4920
tggttggcct tgaactcctg gcttcaagtg atccttctac cttggcctcg gaaagtgttg 4980
ggattacagg cgtgagccac catgactgac ctgtcgtaa tctttaggtt cataaacctg 5040
gctcctaaag gctaaaggct aaatatttgt tggagaaggg gcattggatt ttgcattgagg 5100

FIGURE 4D

atgattctga cctggggaggg caggtcagca ggcacatctcg ttgcacagat agagtgtaca 5160
ggtctggaga acaaggagtg gggggttatt ggaattccac attgtttgct gcacgttga 5220
ttttgaaatg ctaggaaact ttgggagact cataattctg ggctagagga tctgtggacc 5280
acaagatctt tttatgatga cagtagcaat gtatctgtgg agctggattc tgggttggga 5340
gtgcaaggaa aagaatgtac taaatgcca gacatctatt tcaggagcat gaggaataaa 5400
agttctagtt tctggtctca gagtggtgca gggatcaggg agtctcacaa tctcctgagt 5460
gctgggtct tagggcacac tgggtttgg agtgcaaagg atctaggcac gtgaggctt 5520
gtatgaagaa tcggggatcg tacccacccc ctgtttctgt ttcatcctgg gcatgttcc 5580
tctgccttg tcccctagat gaagtctcca tgagctacaa gggctggtg catccagggt 5640
gatctagtaa ttgcagaaca gcaagtgcta gctctccctc cccttccaca gctctgggtg 5700
tgggagggggg ttgtccagcc tccagcagca tggggagggc ctggtcagc ctctgggtgc 5760
cagcaggca ggggcggagt cctgggaat gaaggttta tagggctcct gggggaggct 5820
ccccagcccc aagctt 5836

FIGURE 5A

aagctttta gtgcattttaga cagttagtgcgt gtcgtctaa cccaaatgtac ctgggctcca	60
tactcagccc cagaaggtaaa gggtgaagct gggtgagcc aaaccaggca agcctaccct	120
cagggtcccc agtggcctga gaaccattgg acccaggacc cattacttctt agggttaaggaa	180
aggtaaaaac accagatcca accatggtctt gggggacag ctgtcaaattt cctaaaaata	240
tacctgggag aggagcaggc aaactatcac tgccccagg tctctgaaca gaaacagagg	300
ggcaacccaa agtccaaatc caggtgagca ggtgcaccaa atgcccagag atatgacgag	360
gcaagaagtg aaggaaccac ccctgcatca aatgtttgc atggaaagga gaagggggtt	420
gctcatgttc ccaatccagg agaatgcatt tggatctgc cttttctca ctccttgggt	480
agcaagacta agcaaccagg actctggatt tggggaaaga cggttattttg tggaggccag	540
tgtgacaat cccacgggg cctaggtgaa gagggcagga aggctcgaga cactggggac	600
tgagtaaaa ccacacccat gatctgcacc acccatggat gtccttcattt tgctcacctt	660
tctgttgcata tcagatggcc ccattttctg taccttcaca gaaggacaca ggctagggtc	720
tgtgcatggc cttcatcccc gggccatgt gaggacagca ggtggaaag atcatgggtc	780
ctctgggtc ctgcaggggcc agaacattca tcacccatac tgaccccta gatggaaatg	840
gttccctgg ggctggccca acggggcctg ggcaggggag aaaggacgac agggggacagg	900
gaggaagggt catcgagacc cagcctgaa ggttcttgc tctgaccatc caggattac	960
ttccctgcatttcat ttacccatgg tcattttccc tcagcaatga ccagctctgc ttccctgatct	1020
cagccctccca ccctggacac agcacccag tccctggccc ggctgcattcc acccaataacc	1080
ctgataaccc aggacccatt acttcttaggg taaggagggt ccaggagaca gaagctgagg	1140
aaaggcttgcata agaagtccaca tctgtctgg ccagaggggaa aaaaccatca gatgctgaac	1200
caggagaatg ttgacccagg aaaggacccg aggacccaaag aaaggagtca gaccaccagg	1260
gtttgcctga gaggaaggat caaggccccg agggaaagca gggctggctg catgtgcagg	1320
acactgggtgg ggcataatgtg tcttagatttcc tccctgaattt cagtgtccctt gccatggccca	1380
gactctctac tcaggcctgg acatgctgaa ataggacaat ggccttgtcc tctctccccca	1440
ccattttggca agagacataa aggacattcc aggacatgcc ttccctggag gtccagggttc	1500
tctgtctcac acctcaggga ctgttagtttac tgcattcagcc atggtaggtt ctgtatctcac	1560
ccagcctgtc caggcccttc cactctccac tttgtgacca tgtccaggac caccctcag	1620
atccctgagcc tgcaaaatacc cccttgcgtt gggtggat tcaagtaaaca gtgagctcct	1680

FIGURE 5B

atccagcccc cagagccacc tctgtcacct tcctgctggg catcatccca ctttcacaag	1740
cactaaagag catggggaga cctggctagc tgggttctg catcacaaaag aaaataatcc	1800
cccaggttcg gattcccagg gctctgtatg tggagctgac agacctgagg ccaggagata	1860
gcagaggtca gcccttaggga gggtggtca tccacccagg ggacagggt gcaccagct	1920
tgctactgaa agggcctccc caggacagcg ccacagccc tgcctgagag ctttgctaaa	1980
cagcagtca aggaggccat ggcagtggct gagctcctgc tccaggcccc aacagaccag	2040
accaacagca caatgcagtc ctccccaaac gtcacaggc accaaaggaa aactgaggtg	2100
ctacctaacc ttagagccat cagggagat aacagccaa ttccccaaac aggccagttt	2160
caatccccatg acaatgaccc ctctgctctc attctccca aaataggacg ctgattctcc	2220
cccaccatgg atttctccct tgtcccgga gcctttctg ccccttatga tctggcact	2280
cctgacacac acctcctctc tggtgacata tcagggtccc tcactgtcaa gcagtccaga	2340
aaggacagaa ctttggacag cgcccatctc agttcacccc ttccctccttc acagggtca	2400
gggcaaagaa taaatggcag aggccagtga gcccagagat ggtgacagggc agtgacccag	2460
gggcagatgc ctggagcagg agctggcgg gceacaggga gaaggtgatg caggaaggga	2520
aacccagaaa tgggcaggaa aggaggacac aggctctgtg gggctgcagc ccagggttgg	2580
actatgagtg tgaagccatc tcagcaagta agggcaggc ccatgaacaaa gagtgggagc	2640
acgtggcttc ctgctctgta tatgggtgg gggattccat gccccataga accagatggc	2700
cggggttcag atggagaagg agcaggacag gggatcccc gataggagg accccagtgt	2760
ccccacccag gcaggtgact gatgaatggg catgcagggt cctcctggc tggctctcc	2820
ctttgtccct caggattccct tgaaggaaca tccggaagcc gaccacatct acctgggtgg	2880
ttctggggag tccatgtaaa gccaggagct tgggttgcta ggaggggtca tggcatgtgc	2940
tggggcacc aaagagagaa acctgagggc aggaggacc tggtctgagg aggcattggaa	3000
gcccagatgg ggagatggat gtcagaaag gctgccccat cagggagggt gatagaatg	3060
gggggtctgt gggagtggc acgtgggatt ccctggctc tgccaagttc cctccatag	3120
tcacaacctg gggacactgc ccatgaaggg gcgcctttgc ccagccagat gctgctggtt	3180
ctgccccatcc actaccctct ctgctccagc cactctgggt ctttctccag atgcctggaa	3240
cagccctggc ctggggctgt cccctgagag gtgttggag aagctgagtc tctggggaca	3300
ctctcatcag agtctgaaag gcacatcagg aaacatccct ggtctccagg actaggcaat	3360

FIGURE 5C

gagggaaaggg cccccagctcc tccctttgcc actgagaggg tcgaccctgg gtggccacag	3420
tgacttctgc gtctgtccca gtcaccctga aaccacaaca aaaccccccagc cccagaccct	3480
gcaggtacaa tacatgtggg gacagtctgt acccaggggg agccagttct ctcttcctag	3540
gagaccgggc ctcagggctg tgcccgggc aggccggggc agcacgtgcc tgccttgag	3600
aactcgggac cttaaagggtc tctgtctgt gaggcacagc aaggatcctt ctgtccagag	3660
atgaaagcag ctccctgcccc tcctctgacc tcttcctcct tcccaaatct caaccaacaa	3720
ataggtgttt caaatctcat catcaaatct tcatccatcc acatgagaaa gctaaaaacc	3780
caatggattt acaacatcaa gagttgaaac aagtggacat ggagatgtta cttgtggaaa	3840
ttagatgtg ttcagctatc gggcaggaga atctgtgtca aattccagca tggttcagaa	3900
aatcaaaaaa gtgtcacagt ccaaataatgtgc aacagtgcag gggataaaaac tgtggtgc	3960
tcaaaactgag ggatattttg gaacatgaga aaggaaggga ttgctgctgc acagaacatg	4020
gatgatctca cacatagagt taaaagaaag gagtcaatcg cagaatagaa aatgatcact	4080
aattccaccc tataaaagt tccaagagga aaacccaaatt ctgctgctag agatcagaat	4140
ggaggtgacc tgccttgc aatggctgtg agggcacgg gagtgtcact tagtgcaggc	4200
aatgtgccgt atcttaatct gggcagggt ttcatgagca cataggaatg cagacattac	4260
tgctgtgttc attttacttc accggaaaag aagaataaaa tcagccggc gcgggtggctc	4320
acgcctgtaa tcccagcaact ttagaggct gaggtggca gattacttga ggtcaggagt	4380
tcaagaccac cctggccaat atggtaaac cccggctcta ctaaaaatac aaaaattagc	4440
tggcatggt ggtgcgcgcc tgaatccca gctactcggg aggctgaggc tggacaattt	4500
cttggaccca ggaagcagag gttgcagtga gccaagattt tgccactgca ctccagcttgc	4560
ggcaacagag ccagactctg taaaaaaaaaaa aaaaaaaaaaaa aaaaaaagaa agaaagaaaa	4620
agaaaaagaaa gtataaaatc tctttgggtt aacaaaaaaaaa gatccacaaa acaaacacca	4680
gcttttatca aacttacaca actctgccag agaacaggaa acacaaatac tcattaactc	4740
acttttgtgg caataaaacc ttcatgtcaa aaggagacca ggacacaatg aggaagtaaa	4800
actgcaggcc ctacttgggt gcagagaggg aaaatccaca aataaaacat taccagaagg	4860
agctaagatt tactgcattt agttcattcc ccaggtatgc aaggtgattt taacacctga	4920
aaatcaatca ttgcctttac tacatagaca gattagctag aaaaaaattta caactagcag	4980
aacagaagca atttggccctt cctaaaattc cacatcatat catcatgatg gagacagtgc	5040
agacgccaat gacaataaaa agagggaccc ccgtcacccg gtaaacatgt ccacacagct	5100

FIGURE 5D

ccagcaagca cccgtttcc cagtgaatca ctgtaacctc cccttaatc agccccaggc	5160
aaggctgcct gcgatggcca cacaggctcc aaccctgtgg cctcaacctc ccgcagaggc	5220
tctcccttgg ccaccccatg gggagaagcat gaggacaggg cagagccctc tgatgcccac	5280
acatggcagg agctgacgcc agagccatgg gggctggaga gcagagctgc tggggtcaga	5340
gcttcctgag gacacccagg cctaaggaa ggcatcccc tggatggggg caaccaggct	5400
ccgggctcca acctcagagc ccgcattggga ggagccagca ctctaggcct ttccctagggt	5460
gactctgagg ggaccctgac acgacaggat cgctgaatgc acccgagatg aaggggccac	5520
cacgggaccc tgctctcgta gcagatcagg agagagtggg acaccatgcc aggccccat	5580
ggcatggctg cgactgaccc aggcactcc cctgcattgca tcagcctcggt taagtcacat	5640
gaccaagccc aggaccaatg tggaaaggaag gaaacagcat ccccttttagt gatggAACCC	5700
aaggctagt caaagagagg ccatgagcag ttaggaaggg tggtccaacc tacagcacaa	5760
accatcatct atcataagta gaagccctgc tccatgaccc ctgcatttaa ataaacgttt	5820
gttaaatgag tcaaattccc tcaccatgag agctcacctg tgtgttaggcc catcacacac	5880
acaaacacac acacacacac acacacacac acacacacac acagggaaag tgcaggatcc	5940
tggacagcac caggcaggct tcacaggcag agcaaacagc gtgaatgacc catgcagtgc	6000
cctggggccc atcagctcaag agaccctgtg agggctgaga tggggctagg caggggagag	6060
acttagagag ggtggggcct ccagggaggg ggctgcaggg agctgggtac tgccctccag	6120
ggagggggct gcagggagct ggtactgcc ctccaggag gggctgcag ggagctgggt	6180
actgcccctcc agggaggggg ctgcagggag ctgggtactg ccctccaggg agggggctgc	6240
agggagctgg gtactgccct ccagggaggc aggacactg ttcccaacag agagcacatc	6300
ttccctgcagc agctgcacag acacaggagc ccccatgact gccctggcc agggtgtgga	6360
ttccaaattt cgtccccat tgggtggac ggaggttgac cgtgacatcc aaggggcattc	6420
tgtgattcca aacttaaact actgtgccta caaaatagga aataacccta ctttttctac	6480
tatctcaaatt tccctaagca caagctagca cccttaat caggaagttc agtcactcct	6540
ggggtcctcc catgccccca gtctgacttg caggtgcaca ggggtggctga catctgtcct	6600
tgctccctcc ttggctcaa ctggccccc tcctgggggt gactgtatggt caggacaagg	6660
gatccttagag ctggcccat gattgacagg aaggcaggac ttggcctcca ttctgaagac	6720
taggggtgtc aagagagctg ggcattccac agagctgcac aagatgacgc ggacagaggg	6780

FIGURE 5E

tgacacaggg ctcagggtt cagacgggtc gggaggctca gctgagagtt cagggacaga	6840
cctgaggagc ctcagtggga aaagaagcac tgaagtggga agttctggaa tggtctggac	6900
aaggcctgagt gctctaagga aatgctccca ccccgatgta gcctgcagca ctggacggtc	6960
tgtgtacctc cccgctgccc atcctctcac agccccgc tctagggaca caactcctgc	7020
cctaacatgc atctttctg tctcattcca cacaaaaggg cctctgggt ccctgttctg	7080
cattgcaagg agtggaggtc acgttcccac agaccaccca gcaacagggt cctatggagg	7140
tgccgtcagg aggatcacac gtcccccacat gcccaggggta ctgactctgg gggtgatgga	7200
ttggcctgga gcccactggt cccctctgtc cctgagggga atctgcaccc tggaggctgc	7260
cacatccctc ctgattctt cagctgaggg cccttcttga aatcccaggg aggactcaac	7320
ccccactggg aaaggcccag tgtggacggt tccacacgag cccagctaag gcccggac	7380
acagatcctg agtgagagaa ccttaggga cacaggtgca cggccatgtc cccagtgc	7440
acacagagca ggggcacatcg gaccctgagt gtgtagctcc cgccactgaa cccagccctt	7500
ccccaatgac gtgacccctg gggtgtcc aggtctccag tccatgccac caaaatctcc	7560
agattgaggg tcctcccttg agtccctgat gcctgtccag gagctgcccc ctgagcaa	7620
ctagagtgcg gagggttggg atttgtggcag taaaacgcac cacattgtc tcaggaagga	7680
aagggaggac atgagctcca ggaaggcga tggcgtcctc tagtgggcgc ctccgttaa	7740
tgagcaaaaa ggggcacgga gagttgagag atcagggtcg gccttgact aaggctcaga	7800
tggagaggac tgaggtgca agagggggct gaagttaggg agtggtcggg agagatggga	7860
ggagcaggta aggggaagcc ccaggaggc cgggggagg tacagcagag ctctccactc	7920
ctcagcattt acattttgggg tggcgtgtc agtggggttc tgtaagttgt agggtgttca	7980
gcaccatctg gggactctac ccactaaatg ccagcaggac tccctccccca agctctaaca	8040
accaacaatg tctccagact ttccaaatgt cccctggaga gcaaaattgc ttctggcaga	8100
atcaactgatc tacgtcagtc tctaaaatgt actcatcagc gaaatccttc acctcttggg	8160
agaagaatca caagtgtgag aggggttagaa actgcagact tcaaaatctt tccaaaagag	8220
ttttacttaa tcagcagttt gatgtcccag gagaagatac atttagagtg ttttagagttg	8280
atgccacatg gctgcctgta cctcacagca ggagcagagt gggtttcca agggcctgta	8340
accacaactg gaatgacact cactgggtt cattacaaag tggaaatgtgg ggaattctgt	8400
agactttggg aaggaaatg tatgacgtga gcccacagcc taaggcagtg gacagttcac	8460
tttggggctc tcaccatcta ggagacatct cagccatgaa catagccaca tctgtcatta	8520

FIGURE 5F

gaaaacatgt ttattaaga ggaaaaatct aggctagaag tgcttatgc tctttttct	8580
ctttatgttc aaattcatat acttttagat cattcctaa agaagaatct atccccctaa	8640
gtaaatgtta tcactgactg gatagtgtg gtgtctact cccaaccctt gtgtggtgac	8700
agtgcctgc ttccccagcc ctggggccctc tctgattcct gagagctttg ggtgctccct	8760
cattaggagg aagagaggaa gggtgtttt aatattctca ccattcaccc atccacctct	8820
tagacactgg gaagaatcag ttgcccactc ttggatttga tcctcgaatt aatgacctct	8880
atttctgtcc ctgtccatt tcaacaatgt gacaggccta agaggtgcct tctccatgtg	8940
attttgagg agaagggtct caagataagt tttctcacac ctcttgaat tacctccacc	9000
tgtgtccca tcaccattac cagcagcatt tggaccctt ttctgttagt cagatgctt	9060
ccaccccttg agggtgtata ctgtatgctc tctacacagg aatatgcaga ggaaatagaa	9120
aaaggaaat cgccattacta ttcagagaga agaagacctt tatgtgaatg aatgagagtc	9180
taaaatccta agagagccca tataaaattha ttaccagtgc taaaactaca aaagttacac	9240
taacagtaaa ctagaataat aaaacatgca tcacagttgc tggtaaagct aaatcagata	9300
ttttttctt agaaaaagca ttccatgtgt gttcagtga tgacaggagt gcccctcagt	9360
caaatgctg cctgttaattt ttgtccctg gcagaatgta ttgtcttttc tccctttaaa	9420
tcttaaatgc aaaactaaag gcagctctg ggccttcc ccaaagtctag ctgcctgcaa	9480
ccagccccac gaagagcaga ggcctgagct tccctggta aaataggggg cttagggagct	9540
taaccttgct cgataaaagct gtgtccctag aatgtcgctc ctgttccctg gggcaccaggc	9600
ctggagggtg gtgagcctca ctggtggct gatgcttacc ttgtccctc acaccagtgg	9660
tcactggaac ttgaacact tggctgtcgc ccggatctgc agatgtcaag aacttctgga	9720
agtcaaatta ctgcccaactt ctccaggca gatactgtg aacatccaaa accatgccac	9780
agaaccctgc ctggggctca caacacatat ggactgtgag caccaagtcc agccctgaat	9840
ctgtgaccac ctgccaagat gcccctaact gggatccacc aatcaactgca catggcaggc	9900
agcgaggctt ggaggtgctt cgccacaagg cagccccat ttgctggag tttcttggca	9960
cctggtagtg gtgaggagcc ttgggaccct caggattact ccccttaagc atagtggga	10020
cccttctgca tccccagcag gtgccccctt ctccagagcc tctctctctg aggtttaccc	10080
agaccctgc accaatgaga ccatgctgaa gcctcagaga gagagatgga gctttgacca	10140
ggagccgctc ttccttgagg gccagggcag ggaaagcagg aggccagcacc aggagtgaa	10200

FIGURE 5G

acaccagtgt ctaagccccct gatgagaaca gggtgttctc tcccatatgc ccataccagg	10260
cctgtgaaca gaatccctct tctgcagtga caatgtctga gaggacgaca tgtttcccag	10320
cctaacgtgc agccatgccc atctaccac tgcctactgc aggacagcac caaccaggag	10380
gctggagaagc tgggagaaga catggaatac ccatggcttc tcacccttctt ccagttccagt	10440
gggcaccatt tatgccttagg acacccaccc gccggcccca ggctcttaag agttaggtca	10500
cctaggtgcc tctgggaggc cgaggcagga gaattgcttg aaccggggag gcagagggtt	10560
cagtgagccg agatcacacc actgcactcc agcctgggtg acagaatgag actctgtctc	10620
aaaaaaaaaaag agaaagatag catcagtggc taccaagggc tagggcagg ggaagggtgga	10680
gagttaatga ttaatagttat gaagtttcta tgtgagatga tgaaaatgtt ctggaaaaaaa	10740
aaatataatgt gtgaggatgt agaatattgt gaatataatt aacggcattt aattgtacac	10800
ttaacatgtat taatgtggca tattttatct tatgtatttgc actacatcca agaaacactg	10860
ggagagggaa agcccaccat gtaaaataca cccaccctaa tcagatagtc ctcattgtac	10920
ccaggtacag gcccctcatg acctgcacag gaataactaa ggatttaagg acatgaggct	10980
tcccagccaa ctgcaggtgc acaacataaa tgtatctgca aacagactga gagtaaagct	11040
gggggcacaa acctcagcac tgccaggaca cacacccttc tcgtggattc tgactttatc	11100
tgacccggcc cactgtccag atcttgggtt gggattggga caagggaggt cataaagcct	11160
gtccccaggg cactctgtgt gagcacacga gacccccc cccccccacc tttaggtctc	11220
cacacataga tctgaccatt aggcattgtg aggaggactc tagcgccggc tcagggatca	11280
caccagagaa tcaggtacag agaggaagac ggggctcgag gagctgtatgg atgacacaga	11340
gcagggttcc tgcagtccac aggtccagct caccctgggtg taggtcccccc atccccctga	11400
tccaggcatt cctgacacag ctcctcccg gagcctcctc ccaggtgaca catcagggtc	11460
cctcaactcaa gctgtccaga gagggcagca ccttggacag cggccacccc acttcactct	11520
tcctccctca cagggctcag ggctcaggggc tcaagtctca gaacaaatgg cagaggccag	11580
tgagccaga gatggtgaca gggcaatgat ccagggcag ctgcctgaaa cgggagcagg	11640
tgaagccaca gatgggagaa gatggttcag gaagaaaaat ccaggaatgg gcaggagagg	11700
agaggaggac acaggctctg tggggctgca gcccaggatg ggactaagtg tgaagacatc	11760
tcagcaggtg aggccaggc ccatgaacag agaagcagct cccacccccc ctgtatgcacg	11820
gacacacaga gtgtgtgggtg ctgtgcccccc agagtcgggc tctcctgttc tggtccccag	11880
qqagtgagaa gtgagggttga cttgtccctg ctccctctg ctaccccaac attcaccc	11940

FIGURE 5H

tcctcatgcc	cctctctctc	aaatatgatt	tggatctatg	tccccgccc	aatctcatgt	12000
caaattgtaa	accccaatgt	tggaggtggg	gccttgcgag	aagtgattgg	ataatgcggg	12060
tggattttct	gcttgatgc	tgtttctgt	atagagatct	cacatgatct	ggttgtttaa	12120
aagtgtgtag	cacctctccc	ctctctctct	ctctctctta	ctcatgctct	gccatgtaa	12180
acgttctgt	ttccccctea	ccgtccagaa	tgattgtaa	tttctgagg	cctccccagg	12240
agcagaagcc	actatgcttc	ctgtacaact	gcagaatgtat	gagcgaatta	aacctcttt	12300
ctttataaaat	tacccagtct	caggtatttc	ttttagtcaa	tgcgaggaca	gactaataca	12360
atcttctact	cccagatccc	cgcacacgct	tagccccaga	catca	tgc	12420
tgcacagcgc	agcctcctgc	cgacaaaagc	aaagtca	aaagtgacaa	aaatctgcat	12480
ttggggacat	ctgattgtga	aagagggagg	acagtacact	tgtagccaca	gagactgggg	12540
ctcacccgagc	tgaaacctgg	tagca	tttgcataacatg	tgc	atgtac	12600
tctagagatc	agtgttgagt	aaaacagcct	ggtctggggc	cgctgtgtc	cccacttccc	12660
tcctgtccac	cagagggcgg	cagagtccct	cccaccctgg	agcctcccc	ggggctgtcg	12720
acctccctca	gccggggcca	cagcccagca	gggtccaccc	tcacccgggt	cacctcgccc	12780
cacgtccctcc	tcgcccctccg	agctcc	acggactctg	tca	gctgcagc	12840
atcggccgccc	cacctgaggc	ttgtcgccg	ccca	tttgag	gcctgtcg	12900
aggcagctcc	tgtcccctac	accccctcct	tcccccggct	cagctgaa	ggcgtctccc	12960
agggcagctc	cctgtgatct	ccaggacagc	tca	gtcc	acaggctcc	13020
tgc	tgc	cc	acttgc	atgc	acgcccccta	13080
gtggaaatccc	agggcccagc	ccagtgcctg	acacgg	gatgtccat	aaatactgg	13200
taaatgtgtg	ggagatctct	aaaaagaagc	atatcac	cgtgtggccc	ccagcagtca	13260
gagtctgttc	catgtggaca	cagggcact	ggcaccagca	tgggaggagg	ccagca	13320
cccgccgctg	ccccaggaat	gggcctcaa	ccccagagc	ttcaga	aggagg	13380
cctgcaggga	atagatcctc	cggcctgacc	ctgcagccta	atccag	agggtc	13440
tcacaccacg	tcgaccctgg	tcagcatccc	tagggcagtt	ccagaca	aggccgggtct	13500
cctcttgc	tccaggggg	gacattgcac	acagacatca	ctcaggaa	ggattccc	13560
ggacaggaac	ctggcttgc	taagga	agtg	gagg	tgaggc	13620

FIGURE 5I

caacagaccc ttctgatctc tcccacatac ctgctctgtt cctttctggg tccttatgagg	13680
accctgttct gccaggggtc cctgtgcaac tccagactcc ctcctggta caccatgggg	13740
aagggtgggt gatcacagga cagtcagcct cgtagagaca gagaccaccc aggactgtca	13800
gggagaacat ggacaggccc tgagccgcag ctcagccaac agacacggag agggagggtc	13860
ccccctggagc ctcccccaag gacagcagag cccagagtca cccacctccc tccaccacag	13920
tcctctctt ccaggacaca caagacacct cccctccac atgcaggatc tggggactcc	13980
tgagacctct gggcctgggt ctccatccct gggtaactgg cgggggttgtt ggtactggag	14040
acagagggct ggtccctccc cagccaccac ccagtggcc tttttcttagc ccccaagagcc	14100
acctctgtca ctttcctgtt gggcatcatc ccacccccc agagccctgg agagcatggg	14160
gagaccggg accctgctgg gtttctctgt cacaaggaa aataatcccc ctggtgac	14220
agacccaagg acagaacaca gcagaggta gcactggga agacagggtt tcctcccagg	14280
ggatgggggt ccatccaccc tgccgaaaag atttgtctga ggaactgaaa atagaaggga	14340
aaaaagagga gggacaaaag aggcagaaat gagaggggag gggacagagg acacctgaat	14400
aaagaccaca cccatgaccc acgtgatgtc gagaagtact cctgcccctag gaagagactc	14460
agggcagagg gaggaggac agcagaccag acagtcacag cagccttgac aaaacgttcc	14520
tggaactcaa gctttctcc acagaggagg acagagcaga cagcagagac catggagtct	14580
ccctcgcccc ctccccacag atggtgcatc ccctggcaga ggctcctgct cacaggtgaa	14640
gggaggacaa cctggagag ggtggagga gggagctgg gtctcctgg taggacaggg	14700
ctgtgagacg gacagaggc tcctgttggc gcctgaatag ggaagaggac atcagagagg	14760
gacaggagtc acaccagaaa aatcaaattt aactggatt gaaaaggggc aggaaaacct	14820
caagagttct attttcctag ttaattgtca ctggccacta cgtttttaaa aatcataata	14880
actgcatcag atgacacttt aaataaaaac ataaccagg catgaaacac tgtcctcatc	14940
cgcctaccgc ggacattgga aaataagccc caggtgtgg agggccctgg gaaccctcat	15000
gaactcatcc acaggaatct gcagcctgtc ccaggcactg gggtgcaacc aagatc	15056

FIGURE 6A

gaattcagaa ataggggaag gttgaggaag gacactgaac tcaaaggaaa tacagtgatt 60
ggtttatttg tcctctcttc acaacattgg tgctggagga attcccaccc tgaggttatg 120
aagatgtctg aacacccaaac acatagcaact ggagatatga gctcgacaag agtttctcag 180
ccacagagat tcacagccta gggcaggagg acactgtacg ccaggcagaa tgacatggaa 240
attgcgctca cgattggctt gaagaagcaa ggactgtggg aggtgggctt ttagtaaca 300
agagggcagg gtgaactctg attcccatgg gggaatgtga tggcctgtt acaaatttt 360
caagctggca gggataaaaa cccattacgg tgaggacctg tggagggcgg ctgccccaaac 420
tgataaagga aatagccagg tgggggcctt tccattgtt ggggggacat atctggcaat 480
agaaggccttt gagacccttt agggtacaag tactgaggca gcaaataaaaa tgaaatctt 540
ttttcaact ttatactgca tgggtgtgaa gatataattt 600
gaaaggaggg gaggagggaaa gttcctgcag gtctggttt gtctgtgat ccagggggc 660
ttggaactat taaaattaaa taaaattaaa acaagcact gttttaaatt aaattaaatt 720
aaattaaatt ttactttatt ttatcttaag ttctggctt catgtgcagg acgtgcagct 780
ttgttacata gtaaacgtg tgccatggtg gtttgcgtt cctatcaacc catcacctag 840
gtattaagcc cagcatgcat tagctgtttt tccgtacgct ctccctctcc ctgactccca 900
caacaggccc cagtgtgtgt tgttcccttc cctgtgtcca tgtgttctca ttgttcagct 960
cccacttata agtgagaaca tgtggtgaaa ggtttctgt ttctgtgtt gtttgcgtgag 1020
gataatggct tccacctcca tccatgttcc tgcaaggac gtgatctt tctttttat 1080
ggttgcata gaaatttttt tacaatcca attgatattt tatttaatta caagttaatc 1140
taatttagcat actagaagag attacagaag atattagta cattgaatgaa gaaaatataat 1200
aaaataggac gaaggtgaaa tatttagtag gaaaagtata atagttgaaa gaagtaaaaa 1260
aaaatatgca tgagtagcag aatgtaaaag aggtgaagaa cgtaatagtg acttttttaga 1320
ccagattgaa ggacagagac agaaaaattt taaggaattt ctaaaccatg tgagtgttag 1380
aagtagcgt aataacatta aagcctcagg aggagaaaaag aataggaaag gagggaaatat 1440
gtgaataaaat agtagagaca tgtttgatgg attttaaaat atttgaaaga cctcacatca 1500
aaggattcat accgtgccat tgaagaggaa gatggaaaag ccaagaagcc agatgaaaagt 1560
tagaaatattt attggcaaag cttaaatgtt aaaagtccctt gagagaaaagg atggcagaaa 1620
tattggcggg aaagaatgca gaacctagaa tataaattca tcccaacagt ttggtagtgt 1680

FIGURE 6B

gcagctgtag cctttctag ataatacact attgtcatac atcgcttaag cgagtgtaaa 1740
atggtctcct cactttattt atttatatat ttathtagtt ttgagatgga gcctcgctct 1800
gtctccctagg ctggagtgcata atagtgcgtt accactca gcaacctctg cctcctctgt 1860
tcaagtgatt ttcttacctc agcctcccgaa gtagctggga ttacagggtgc gtgccaccac 1920
acccggctaa ttttgtatt tttttagat acgggggtttt gccatgttgg ccaggcttgtt 1980
cttgaactcc tgacatcagg tgatccacct gccttggcct cctaaagtgc tgggattaca 2040
ggcatgagcc accgtgcccacc accactttat ttatTTTta ttttatttt taaatttcag 2100
cttctatttga aatacaggg ggcacatata taggattgtt acatgggtat attgaactca 2160
ggtagtgatc atactaccca acaggttagt tttcaaccca ctccccctct tttcctcccc 2220
attctagtag tgtgcagtgt ctattgttct catgtttatg tctatgtgtgc ctccagggtt 2280
agctccacc tgtaagtgag aacgtgttgtt atttgattttt ctgtccctgt gttaattcac 2340
ttaggattat ggcttccagc tccattcata ttgctgtaaa ggatatgatt cattttcat 2400
ggccatgcag tattccatat tgcgtataga tcacatttc tttctttttt tttttgaga 2460
cgaggtcttgc ttttgcgtcc taggctggag tgcagtagca cgatctcggtc tcactgcaag 2520
cttcacctcc ggggttcacg tcattttctt gtctcagctt cccaaatgc tgggactaca 2580
ggccccggcc accacgtccg gctaattttt ttgtgtgtttt ttagtagaga tgggggttcc 2640
actgtgttag ccaggatggt cttgatctcc tgacattgtgc gtccacctgc ctgggtctcc 2700
caaagtgcgtg ggattacagg ggtgagccac tgcgccccggc ccatatatac cacattttct 2760
ttaaccaatc caccattgat gggcaactag gtagattcca tggattccac agtttgcta 2820
ttgtgtgcag tgtggcagta gacatatgaa tgaatgtgtc ttttggat aatgatttgc 2880
attcctttgg gtatacagtc attaatagga gtgctgggtt gaacgggtgc tctgtttaaa 2940
attctttgag aattttccaa actgtttgcc atagagagca aactaattta cattttccacg 3000
aacagtatat aacgttccccc ttttctccac agctttgtca tcatggttttt ttttttctt 3060
tattttaaaa aagaatatgt ttttgcgttcc acagggtaca tgtgcaggat gtgcagggtt 3120
gttacatagg tagtaaacgt gagccatgggtt ggtttgcgtgc acctgtcaac ccattacctg 3180
ggtagtgatgc cctgcctgca ttagctttt tccctaatgc tctcaactact gccccccct 3240
caccctgaca gggcaaacag acaacccatac gaatggggagg aaatttttgc aatctattca 3300
tctgacaaag gtcaagaata tccagaatct acaaggaact taagcaaattt tttactttt 3360

FIGURE 6C

ataaatagcc actctgactg gcgtgaaatg gatatcatt gtggtttca tttgaatttc 3420
tctgatgatc agtgacgatg agcattttt catatttgtt ggctgctgt acgtttttg 3480
agaagtgtct cttcatgcct ttggccact ttaatggat tatttttgc ttttagtt 3540
aagttcccta tagattctgg atattagact tcttattgga tgcatagttt gtgaatactc 3600
tcttccatc tgttaggtgt ctgttactc tattgatggc ttctttgct gtgccgaagg 3660
atcttagttt aattagaaaac cacctgcca 3720
acttagtc 3780
ctagaattttt gaaagtctga atgtaaacat ttgcattttt aatgcattt gagttagttt 3840
ttgtatatgt gaaaggctca ctctcattttt cttccctct ttctttctt cttcttttc 3900
tttctttctt tctctttctt tctctcttc tttttttt ttgatggagt attgctctgt 4020
tttctttctt tctctttctt tctctcttc tttttttt ttgatggagt attgctctgt 4080
tgcccaggct gcagtgcage ggcacgatct cggctcaactg caacctctgc ctctgggtt 4140
caactgattt tcctgcatca gccttccaag tagctggat tataggcgcc cgccaccacg 4200
ccccactaat ttttgtat ttagtagaga cggggtgtg ccatttttgc caggctgggtt 4260
tgaaactcct gacctcaaac gatctgcctg cttggcctc ccaaagtgc gggattacag 4320
gtgtgagcca ctgtgcccag ccaagaatgt cattttctaa gaggttcaag aacctaaga 4380
tatttggga ctttgagaag agaggaattt atacaggtat tacaaggcaca gcctaattgc 4440
aaatcttgg catggcttgg cttcaagact ttggcttctt aaaagtgc 4500
tttataaaag ctccagctaa gctaccttaa aaggggcctg tatggctgat cactcttctt 4560
gctatactttt acacaaataa acaggccaaa tataatgagg caaaaatttta ttttgc 4620
aaattggtcc tgctatgatt tactcttggt aagaacaggg aaaatagaga aaaattttaga 4680
ttgcatctga ctttttttc tgaatttttataatgcctt caatttgagc taaatcctga 4740
attattttctt ggttgc 4800
acatttatct ggctctttac tagaacagct ttcttgc 4860
cttacagttt tactcttcaa attattgttataatgcctt atagtttcc ttctttgag 4920
aaaactgaag ccatggattt ctgaggacta gagatgactc aacagagctg gtgaatctcc 4980
tcataatgcaat cccactggc tcgatctgct tcaaattgc gatgcactgc tgctaaagct 5040
atacatattaa aaccctcaact aaaggatcag ggaccatcat ggaagaggag gaaacatgaa 5100
attgttaaaggccatggc ggggttagagt gtggaggtca gagcaactcc accttgaata 5160

FIGURE 6D

agaaggtaaa gcaacctatac ctgaaagcta acctgccatg gtggcttctg attaacctct 5160
gttcttaggaa gactgacagt ttgggtctgt gtcattgccc aaatctcatg ttaaattgta 5220
atccccagtg ttccggagggtg ggacttgggtg gtaggtgatt cggtcatggg agtagattt 5280
cttctttgtg gtgttacagt gatagtgagt gagttctcgat gagatctggt cattaaaaag 5340
tgtgtggccc ctccccctcc tctcttggtc ctcctactgc catgtaagat acctgctct 5400
gcttgcctt ctaccataag taaaagcccc ctgaggectc cccagaagca gatgccacca 5460
tgcttcctgt acagcctgca gaaccatcag ccaattaaac ctctttctg tataaattac 5520
cagtctttag tatctcttta cagcagtgtg agaacggact aatacaaggg tctccaaat 5580
tccaagtttta tgtattcttt cttgccaaat agcaggtatt taccataaat cctgtcctta 5640
ggtcaaacaa ctttgatggc atcgtacttc aattgtctta cacattcctt ctgaatgact 5700
cctccccat ggcataataag ccctgggtct tggggataa tggcagaggg gtccaccatc 5760
ttgtctggct gccacctgag acacggacat ggcttctgtt gttaagtctc tattaaatgt 5820
ttctttctaa gaaactggat ttgtcagctt gtttcttgg cctctcagct tcctcagact 5880
ttggggtagg ttgcacaacc ctgcccacca cgaaacaaat gtttaatatg ataaatatgg 5940
atagatataa tccacataaa taaaagctct tggagggccc tcaataattt ttaagagtgt 6000
aaatgtgtcc aaagatggaa aatgttttag aactactgtc ccagagattt tcctgagttc 6060
tagagtgtgg gaatataaaa cctggagctt ggcttcttca gcctagaatc aggagtatgg 6120
ggctgaagtc tgaagcttgg cttcagcagt ttggggttgg cttccggagc acatattga 6180
catgttgcga ctgtgatttgg gggtttggta ttgtcttga atcctaattgt ctgtccttga 6240
ggcatctaga atctgaaatc tgtggtcaga attctattat cttgagtagg acatctccag 6300
tcctgggtct gccttctagg gctggagtct gtatcagtg acccggtctg gcatttcaac 6360
ttcatataca gtgggctatc ttttggtcca tgtttcaacc aaacaaccga ataaaccatt 6420
agaaccttcc cccacttccc tagetgcaat gttaaaccta ggatttctgt ttaataggtt 6480
catatgaata atttcagcct gatccaactt tacattcctt ctaccgttat tctacaccca 6540
ccttaaaaat gcattccaa tatattccct ggattctacc tatatatgtt aatcctggct 6600
ttgccagttt ctatgtcatt aacataccctg attacattc ttttacttta aagtggaaat 6660
aagagtcctt ctgcagagtt caggagttct caagatggcc cttaacttctg acatcaattt 6720
agattcaag ggagtcgcca agatcatcct caggttcagt gattgctggt agccctcata 6780

FIGURE 6E

taactcaatg aaagctgtta tgctcatggc tatggtttat tacagcaaaa gaatagagat 6840
gaaaatctag caagggaaga gttgcatggg gcaaagacaa ggagagctcc aagtgcagag 6900
attcctgttg ttttctccca gtgggtgtcat ggaaagcagt atcttctcca tacaatgatg 6960
tgtgataata ttcaagtgtat tgccaatcag ggaactcaac tgagccttga ttatattgga 7020
gcttgggtgc acagacatgt cgaccacett catggctgaa cttagtact tagccccctcc 7080
agacgtctac agctgatagg ctgtaaccca acattgtcac cataaatcac attgttagac 7140
tatccagtgatg gGCCCAAGCT CCCGTGTAAGA CACAGGGACT CAAACAGGC AGGATATTTC 7200
aaaagcttag agatgacctc ccaggagctg aatgcaaaga CCTGGCCTCT TTGGGCAAGG 7260
agaatccccc accgcacact ctccttcaca gggttattgt gaggatcaaa tgtggtcatg 7320
tgtgtgagac accagcacat gtctggctgt ggagagtgc ttctatgtgt gctaacattg 7380
ctgagtgcta agaaagtatt aggcatggct ttcagcaactc acagatgctc atctaattcct 7440
cacaacatgg ctacagggtg ggcactacta gcctcatttgc acagaggaaa ggactgtgga 7500
taagaagggg gtgaccaata ggtcagagtc attctggatg caaggggctc cagaggacca 7560
tgattagaca ttgtctgcag agaaattatg gctggatgtc tctgccccgg aaagggggat 7620
gcactttcct tgacccctca tctcagatct tgactttgag gttatctcg acttcctcta 7680
tgataccagg agcccatcat aatctctctg tgcctctcc cttccctcg tcttactgcc 7740
cactctccc agtcccatct ccagtgcc aggtgtagcc acagtaccta actctttgca 7800
gagaactata aatgtgtatc ctacaggggg gaaaaaaaaa aagaactctg aaagagctga 7860
cattttacccg acttgcaaac acataagcta acctgcccagt tttgtgtcg tagaactcat 7920
gagactcctg ggtcagagggc aaaagattt attaccacca gctaaggagg cagcatgaac 7980
tttgcgttca catttgcgtca ctttgccttcc caattcataat gggatgtca gagcagttca 8040
ggtggtgga cacagggggtt tggcaaaag gtgagcaacc taggcttaga aatcctcaat 8100
cttataagaa ggtacttagca aacttgcctca gtcttgcgtat ctgacggaga tattatctt 8160
ataattgggt taaaaggcaga cctactctgg aggaacatata tggatatttatt gtcctgaaca 8220
gtaaacaaat ctgctgtaaa atagacgtta actttattat ctaaggcagt aagcaaacct 8280
agatctgaag gcgataccat cttgcaaggc tatctgctgt acaaataatgc ttgaaaagat 8340
ggtccagaaa agaaaacggt attattgcct ttgctcagaa gacacacaga aacataagag 8400
aaccatggaa aattgtctcc caacactgtt caccacagac cttccactct tgcgtcagg 8460
acagtcctaa catcccatca ttagtgcgtc taccacatct ggcttcaccg tgcctaaacca 8520

FIGURE 6F

agatttctag gtccagttcc ccaccatgtt tggcagtgcc ccactgccaa ccccagaata 8580
agggagtgtc cagaattccg aggggacatg ggtggggatc agaacttctg ggcttgagtg 8640
cagagggggc ccatactcct tggttccgaa ggaggaagag gctggagggtg aatgtccttg 8700
gaggggagga atgtgggttc tgaactctt aatccccaaag ggaggagact ggtaaggccc 8760
cagcttccga ggtactgacg tgggaatggc ctgagaggc taagaatccc gtatcctcg 8820
gaaggagggg ctgaaattgt gagggggtga gttgcagggg tttgttagct tgagactcct 8880
tggtgggtcc ctgggaagca aggactggaa ccattggctc cagggtttgg tgtgaaggta 8940
atgggatctc ctgattctca aagggtcaga ggactgagag ttgcccattgc tttgatcttt 9000
ccatctactc cttactccac ttgagggtta tcacctactc ttctagttcc acaagagtgc 9060
gcctgcgcga gtataatctg cacatgtgcc atgtcccgag gcctggggca tcattccactc 9120
atcattcagc atctgcgcta tgcggggcag gcccggcaca tgacgtcatg tagctgcgac 9180
tatccctgca gcgcgcctct cccgtcacgt cccaaccatg gagctgtgga cgtgcgtccc 9240
ctgggtggatg tggcctgcgt ggtgccaggc cggggcctgg tgtccgataa agatcctaga 9300
accacaggaa accaggactg aaaggtgcta gagaatggcc atatgtcgct gtccatgaaa 9360
tctcaaggac ttctgggtgg agggcacagg agcctgaact tacgggtttg ccccagtcca 9420
ctgtcctccc aagtgagtct cccagatacg aggcactgtg ccagcatcaag cttcatctgt 9480
accacatctt gtaacaggga ctacccagga ccctgatgaa caccatggtg tgtgcaggaa 9540
gaggggggtga aggcattggac tcctgtgtgg tcagagccca gagggggccca tgacgggtgg 9600
ggaggaggct gtggactggc tcgagaagtg ggatgtgggt gtgtttgatt tcctttggcc 9660
agataaaagtg ctggatatacg cattgaaaac ggagtatgaa gaccagttag aatggagggt 9720
caggttggag tttagtttaca gatggggtaa aattctgtt cggatgagggt tggggattgg 9780
caatctaaag gtggtttggg atggcatggc tttggatgg aaatagggtt gttttatgt 9840
tggctggaa gggtgtggg attgaattgg ggatgaagta ggttttagtt tggagataga 9900
atacatggag ctggctattg catgcgagga tgtgcattag tttgggttga tctttaata 9960
aaggaggcta tttaggttgtt cttgaatttag attaagggtt gttgggttga tgggttgggc 10020
ttgtgggtga tgtgggttggta ttgggtgtg ttaaattggt ttgggtcagg ttttgggttga 10080
ggttatcatg gggatgagga tatgtttggg acatggattc aggtgggtct cattcaagct 10140
gaggcaaatt tccttcaga cggtcattcc agggAACGAG tgggtgtgtg gggaaatca 10200

FIGURE 6G

ggccactggc tgtgaatatac cctctatcct ggtcttgaat tttgattatc tatgtccatt 10260
ctgtctcctt cactgtactt ggaattgatc tggtcattca gctggaaatg ggggaagatt 10320
tttgtcaatt cttgagacac agctgggtct ggatcagcgt aagccttcct tctggttta 10380
ttgaacagat gaaatcacat ttttttttc aaaatcacag aaatcttata gagtaacag 10440
tggactctta taataagagt taacaccagg actcttattc ttgattctt tctgagacac 10500
caaatgaga tttctcaatg ccaccctaat tctttttttt tttttttttt ttttgagac 10560
acagtctggg tcttttgc tcgtcactcag gctggagcgc agtgggtgtga tcatacgctca 10620
ctgaaccctt gacccctgg acttaaggga tcctcctgct tcagccctt gatgtatgg 10680
ggctacaggt gcttgcacc acacccggc aattaaattt tttttttttt ttttagaga 10740
aagggtctca ctttggccctt ctggctgatc ttgaacttct gacttcaagt gattcttcag 10800
ccttggactc ccaaaggact gggattgctg gcatgagcca ctcaccgtgc ctggcttgc 10860
gcttaatctt ggagtgtata aacctggctc ctgatagcta gacatttcag tgagaaggag 10920
gcattggatt ttgcatgagg acaattctga cctaggaggg caggtcaaca ggaatcccc 10980
ctgtacctgt acgttgtaca ggcattggaga atgaggagtg aggaggccgt accggAACCC 11040
catattgttt agtggacatt ggatttgaa ataataggga acttggctcg ggagagtcat 11100
atttctggat tggacaatat gtggatcac aaggtttat gatgagggag aaatgtatgt 11160
ggggaccat tttctgagtg tggaaatgca agaattcagag agtagctgaa tgccaaacgct 11220
tctatttcag gaacatggta agttggaggt ccagctctcg ggctcagacg ggtataaggga 11280
ccaggaagtc tcacaatccg atcattctga tatttcaggg catatttagt ttggggtgca 11340
aaggaagtac ttgggactta ggcacatgag actttgtatt gaaaatcaat gattggggct 11400
ggccgtggtg ctcacgcctg taatctcatc actttggag accgaagtgg gaggatggct 11460
tgatctcaag agttggacac cagcctaggc aacatggcca gaccctctct ctacaaaaaa 11520
ataaaaaatt agctggatgt ggtggatgt gcttgggtc tcaatctatcc tggaggctga 11580
gacaggagaa tcgggtgagt ctgggagttc aaggctacag ggagctgcga tcacgcccgt 11640
gcactccagc ctggaaaca gagtggact gtctcagaat tttttaaaaa aagaatcagt 11700
gatcataccca acccctgttg ctgttcatcc tgacccctgccc ttctctggct ttgtcccta 11760
gatcacaatct ccatgatcca taggcctgc ccaatctgac ctcacaccgt ggaaatgcct 11820
ccagactgat ctatgtatgt tggaaacagca agtgctggct ctccctcccc ttccacagct 11880
ctgggtgtgg gagggggttg tccagccctc agcagcatgg ggagggcctt ggtcagcata 11940

FIGURE 6H

taggtgccaa cagggcaagg gcggggtcct ggagaatgaa ggctttatag ggctcctcag 12000
ggaggcccccc cagccccaaa ctgcaccacc tggccgtgga caccgg 12047

FIGURE 7

cgagcggccc ctcagctcg ggcggccagcc ccgcaaggct cccgggtgacc actagagggc 60
gggaggagct cctggccagt ggtggagagt ggcaaggaag gacccttaggg ttcatcgag 120
cccaggtta ctcccttaag tggaaatttc ttccccact ctccttggc tttctccaag 180
gagggAACCC aggctgctgg aaagtccggc tggggcgggg actgtgggtt caggggagaa 240
cgggggtgtgg aacgggacag ggagcggta gaagggtggg gctattccgg gaagtgggtgg 300
ggggagggag cccaaaacta gcacctagtc cactcattat ccagccctct tatttctcg 360
ccgcctctgct tcagtggacc cggggaggc ggggaagtgg agtgggagac cttaggggtgg 420
gcttcccgac cttgctgtac aggacctcga cctagctggc tttgttcccc atccccacgt 480
tagttgtgc cctgaggcta aaactagagc ccaggggccc caagttccag actgcccctc 540
ccccctcccc cggagccagg gagtggtgg tgaaaggggg aggccagctg gagaacaaac 600
gggttagtcag ggggttgagc gattagagcc cttgtaccct acccaggaat gttggggag 660
gaggaggaag aggtaggagg taggggaggg ggcggggttt tgtcacctgt cacctgctcg 720
ctgtgcctag ggcgggccc cggggagtgg ggggaccggc ataaagcggt aggcgcctgt 780
gcccgcctca cctctcaagc agccagcgcc tgcctgaatc tttctgccc cctccccacc 840
catttcacca ccaccatg 858

FIGURE 8

aagcttccac aagtgcattt agcctctcca gtattgctga tgaatccaca gttcagggtc 60
aatggcggtc aaaacttgat caaaaatgac cagactttat attcttacac caacatctat 120
ctgattggag gaatggataa tagtcatcat gtttaaacat ctaccattcc agttaagaaa 180
atatgatagc atcttgttct tagtctttt cttaataggg acataaaagcc cacaataaaa 240
aatatgcctg aagaatggga caggcattgg gcattgtcca tgcctagtaa agtactccaa 300
gaaccttattt gtatactaga tgacacaatg tcaatgtctg tgtacaactg ccaactggga 360
tgcaagacac tgcccatgcc aatcatcctg aaaagcagct ataaaaagca ggaagctact 420
ctgcacccttg tcagtgaggt ccagataacct acag 454

FIGURE 9

g atg acc ggc tca acc atc gcg ccc aca acg gac tat cgc aac acc act 49
Met Thr Gly Ser Thr Ile Ala Pro Thr Thr Asp Tyr Arg Asn Thr Thr
1 5 10 15

gct acc gga cta aca tct gcc cta aat tta ccc caa gtt cat gcc ttt 97
Ala Thr Gly Leu Thr Ser Ala Leu Asn Leu Pro Gln Val His Ala Phe
20 25 30

gtc aat gac tgg gcg agc ttg gac atg tgg tgg ttt tcc ata gcg ctt 145
Val Asn Asp Trp Ala Ser Leu Asp Met Trp Trp Phe Ser Ile Ala Leu
35 40 45

atg ttt gtt tgc ctt att att atg tgg ctt att tgt tgc cta aag cgc 193
Met Phe Val Cys Leu Ile Met Trp Leu Ile Cys Cys Leu Lys Arg
50 55 60

aga' cgc gcc aga ccc ccc atc tat agg cct atc att gtg ctc aac cca 241
Arg Arg Ala Arg Pro Pro Ile Tyr Arg Pro Ile Ile Val Leu Asn Pro
65 70 75 80

cac aat gaa aaa att cat aga ttg gac ggt ctg aaa cca tgt tct ctt 289
His Asn Glu Lys Ile His Arg Leu Asp Gly Leu Lys Pro Cys Ser Leu
85 90 95

ctt tta cag tat gat taa 307
Leu Leu Gln Tyr Asp
100

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/20718

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/86 C12N5/10 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 698 443 A (HENDERSON DANIEL ROBERT ET AL) 16 December 1997 (1997-12-16) cited in the application the whole document ---	1-17, 23-28
Y	SEMENTZA G. L. ET AL.: "Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 51, 1996, pages 32529-32537, XP002129236 the whole document, especially Fig. 10 ---	1-10, 14-17, 23-28

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

31 January 2000

11/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mand1, B

INTERNATIONAL SEARCH REPORT

International Application No	
PCT/US 99/20718	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 13508 A (DANA FARBER CANCER INST INC ;KAELIN WILLIAM JR (US); FINE HOWARD A) 2 April 1998 (1998-04-02) page 3, last paragraph - paragraph 2 page 9, line 1 - line 11 ---	1-8, 11, 12, 14-17, 23-28
Y	WO 98 06864 A (US HEALTH ;MOONEN CHRIT (US)) 19 February 1998 (1998-02-19) page 10, line 36 -page 12, line 8 ---	1-8, 13-17, 23-28
A	EP 0 845 537 A (CHIRON CORP) 3 June 1998 (1998-06-03) page 22, line 31 - line 34 ---	18-22
A	WO 96 17053 A (GENETIC THERAPY INC ;HALLENBECK PAUL L (US); CHANG YUNG NIEN (US);) 6 June 1996 (1996-06-06) cited in the application the whole document ---	1-28
A	RINSCH C. ET AL.: "A GENE THERAPY APPROACH TO REGULATED DELIVERY OF ERYTHROPOIETIN AS A FUNCTION OF OXYGEN TENSION." HUMAN GENE THERAPY, vol. 8, no. 16, November 1997 (1997-11), pages 1881-1889, XP000867701 the whole document ---	9,10
A	ZWICKER J. ET AL.: "CELL CYCLE REGULATION OF THE CYCLIN A, CDC25C AND CDC2 GENES IS BASED ON A COMMON MECHANISM OF TRANSCRIPTIONAL REPRESSION" EMBO JOURNAL, vol. 14, no. 18, 1 January 1995 (1995-01-01), pages 4514-4522, XP002038970 ISSN: 0261-4189 the whole document -----	11,12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 20718

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 27 and 28, as far as in vivo application is concerned, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte onal Application No

PCT/US 99/20718

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5698443	A	16-12-1997		AU 6393296 A CA 2222457 A EP 0844888 A JP 11508770 T WO 9701358 A US 5871726 A	30-01-1997 16-01-1997 03-06-1998 03-08-1999 16-01-1997 16-02-1999
WO 9813508	A	02-04-1998		AU 4592697 A	17-04-1998
WO 9806864	A	19-02-1998		AU 4241697 A EP 0922110 A	06-03-1998 16-06-1999
EP 0845537	A	03-06-1998		AU 5915394 A AU 648261 B AU 6185390 A AU 694685 B AU 7058496 A CA 2066053 A EP 0487587 A JP 4507196 T US 5662896 A WO 9102805 A US 5716826 A US 5591624 A US 5691177 A US 5716832 A US 5888502 A US 5997859 A US 5856185 A US 5716613 A US 5851529 A US 5830458 A	16-06-1994 21-04-1994 03-04-1991 23-07-1998 16-01-1997 19-02-1991 03-06-1992 17-12-1992 02-09-1997 07-03-1991 10-02-1998 07-01-1997 25-11-1997 10-02-1998 30-03-1999 07-12-1999 05-01-1999 10-02-1998 22-12-1998 03-11-1998
WO 9617053	A	06-06-1996		AU 4504396 A CA 2206179 A EP 0791050 A FI 972225 A JP 10509880 T NO 972373 A US 5998205 A	19-06-1996 06-06-1996 27-08-1997 16-07-1997 29-09-1998 25-07-1997 07-12-1999